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The present invention relates to novel proteins, referred to 
herein as amidated glial cell line-derived neurotrophic factor 
(GDNF) peptides (or "Amidated Dopamine Neuron Stimu-
lating peptides (ADNS peptides)"), that are useful for treat-
ing brain diseases and injuries that result in dopaminergic 
deficiencies. 
8 Claims, 20 Drawing Sheets 
U.S. Patent Mar.7,2017 Sheet 1 of 20 US 9,586,992 B2 
Mature HumanGDNF 
TCA CCA GAT .AAA CJY\ A'l'f'-3 (J{]".\ (~'l\~ Cl'!' CCT At.Vl AGA. GAG C(K3 Al\'l' 
Ser Pro Asp L2''9 Gln Met: Ala Val Leu Pro A:rg Arg Glu Arg J\sn 
s 10 15 
CG(} C:AG GC'L' GCA GCT GO:' Ji.AC C{)'\ GIV~ !lli!L' TCC AGA GGA AAA GGT 
Arg Gln Ala Ala Al.a Ala A911 ~>:ro Glu Asn Ser. Arr:j Gly !iys Gly 
20 25 :w 
0313 Ar.:iA 03<.: Cl!;{; f\GG GGC lilt.A lo.r-...C CO.'J GGI' T(:;i,· G'TC 't"'l'A AC"r GCA 
At9 /\t'?J Gly G1n AJ;g Gly l;ys Asn A.rg Gly C'ys Val Leu ·rhr Al.a 
35 40 45 
A'i'A Ci\T IT!.;. l\AT GTC ACT DAC 't'TG GGI' CTG (;('.;!'.; TAT l'.3AA ACC AJ\G 
Ill.!! H:Ls r,eu Afm v.;l Tb1; f\SP, Leu G.ly LtiU Gly 'fyr Glu 'tl1Y' Lya 
50 °''L' ,),) 60 
t:JJ\O GAA WG A.TT TI'T' J.V.AJ TN:::. ·me AJ.3'~ Gt± 'T'CT TCiC GAT (J('J\ m::'r 
Glu Gl.u Leu Ile Phe Arg '1'yr Cy'fJ Ser. (;ly S1:'n: C'ya J.l.ap Ali'.l P,J.:;i 
65 IQ 75 
Gl\.G AC.A l\C{] '!'AC GAC AA.I\ ATA TTG l\.n,r1 M···· 'I'TA TL\C' AGA AAT ADA. 
Glu 'l'br Thr '1'.YL' AtJp Lyn :rJe Leu Lys Aua Lt:t\l Ser lu:·g tu1n Arg 
HO 8'' '.)0 
N3G crG CH'G AC~1f Cll\C: ~h..Jt."ri. GTl~ 0'30 Cl>G (;(:.i\. 'l'Ctl' 'JY.X..: AG..?.. CC'C l~.1':' 
P;.rg Leu 1;foJ. 8er At>p I,yu V0iJ 0·1y Gl.n Al<t Cys Cy·:::; Ar:g P:r.'(> ne 
95 10.D 10'5 
GCC 'f'l''l' t;;i'\'l' (~·/(' Gf\C c·nc; 'l'C'G ·rrr TTA (;t\·r {~1~vr AA(:· (:'Pt~ z::r1· 11?.AC 
Jt.Ja Phi;~ J»sp Arn{? /\sp Lftll S(2r mv:: Leu i\op /\Hp AB1'1 1'21l Va1 Tyr 
11.0 125 120 
Cl«T 1'\Tl' (~i'l\ t~.(ll\. i1l\U Ci\T (rcx: GC"°l' l!tlt.1\ l\CK3 '1\'.J'~~ (f(_?l\ "1'{31' l"<l'C 
J]i 8 1.1 ~s lr.-;,w li:r·s~ JJ'tr-i J!i.n ~:if?J .... Alu. Ii]' CJ fl.cg t;yn (l:\y (~~{·,fl: tlE'o 
125 DD 
F1G. 1 
U.S. Patent Mar.7,2017 Sheet 2 of 20 US 9,586,992 B2 
Human Glial-eell 'Derived Neurotrophic Factor Precursor1 isotype 1 (GDNF} 
1 MKLWDWAVCLVLLHTASAFPLPAGKRPPE 
31 APAEDRSLGRRRAPFALSSDSNMPEDYPDQ 
61 FDDVMDFIQATIKRLKRSPDKQMAVLPRRE 
91 RNRQAAAANPENSRGKGRRGQRGKNRGCVL 
121 TAIHLNVTDLGLGYETKEEUFRYCSGSCO 
151 AAETTYDKILKNLSRNRRLVSDKVGQACCR 
181 PIAFDDDLSFLDDNLVYHILRKHSAKRCGC 
211 I 
Signal Peptidase 
FPLPAGKRPPE 
31 APAEDRSLGLRRRAP~ALSSDSNMPEOYPDQ 
61 FDDVMDFIQATIKRLKRSPDKQMAVLPRRE 
91 RNRQAAAANPENSRGKGRRGQRGKNRGCVL 
121 TAIHLNVTDLGLGYETKEEUFRYCSGSCD 
151 AAETTYDKILKNLSRNRRLVSOKVGQACCR 
181 PIAFDDDLSFLDDNLVYHILRKHSAKRCGC 
211 I 
~Paired Basics-Specific"' endopeptidase 
(furin-like protease or PCr) that cleaves on the 
carboxy side of KR and RR sequences 
FPLPAGKF(L 
PPEAPAEDfSLGRR 
ERNRQAAAANPENSRGKGRR 
FPLPAG 
Caro-0xypeptidase H that remcwes C-terminal 
I< and R residues 
PPEAPAEDRSLG 
ERNRQA.A.AANPENSRGKG i Peptld}'lglycine Amidating Monooxygenase (PAM) 
FPL PA-amide 
PPEAPAEDRSL~amide 
ERNROAAAANPENSRGK~amide 
FIG. 2 
U.S. Patent Mar.7,2017 Sheet 3 of 20 US 9,586,992 B2 
Precursor Segments 
1. FPLPAGKR 
2. KRPPEA.PAEDRSLGRR 
J. RRERNRQAAAANPENSRGKGRR 
FIG. 3 
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DOPAMINERGIC UPREGULATION 
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FIELD OF THE INVENTION 
The present invention relates to novel proteins, referred to 
herein as amidated glial cell line-derived neurotrophic factor 
(GDNF) peptides (or "Amidated Dopamine Neuron Stimu-
lating peptides (ADNS peptides)"), that are useful for treat-
ing brain diseases and injuries that result in dopaminergic 
deficiencies. 
BACKGROUND OF THE INVENTION 
Neurotrophic factors are endogenous proteins that modu-
late cell signaling pathways regulating stem cell prolifera-
tion, neuronal differentiation, differentiation, growth and 
regeneration (Barde Y, "Trophic factors and neuronal sur-
vival", Neuron 2:1525-1534 (1989); Gatz, R., et al., "The 
conservation of neurotrophic factors during vertebrate evo-
lution", Comp Biochem Physiol Pharmacol Toxicol Endo-
crinol 108: 1-10 (1994); and Goldman, S. A., "Adult neu-
rogenesis: from canaries to the clinic", J Neurobiol 36: 
267-86 (1998)). They are generally small, soluble proteins 
with molecular weights between 13 and 24 KDa and often 
function as homodimers. Because of this physiological role, 
neurotrophic factors are useful in treating the degeneration 
of nerve cells and the loss of differentiated function that 
occurs in a variety of neurodegenerative diseases. 
Many neurotrophic factors are both neuroprotective (pro-
tecting neurons from injury) and neurorestorative (promot-
ing structural and functional regeneration). The best defined 
protective functions are seen during neural development. 
During development, excessive numbers of neurons are 
generated in many brain regions. Developing neurons that 
fail to make connections with appropriate trophic factor 
producing target cells are deprived of necessary neuro-
trophic factors and die. Those neurons that establish con-
nections survive and function properly (e.g. NGF; see 
Campenot, R. B. and Maclnnis, B. L. "Retrograde transport 
of neurotrophins: fact and function", J Neurobiol 58: 217-
2 
229 (2004)). Neurotrophic factors are also capable of pro-
moting the re-growth of damaged neurons and their pro-
cesses both in vitro and in animal models (see Lad, S. P. et 
al., "Individual and combined effects of TrkA and p75NTR 
5 nerve growth factor receptors: A role for the high affinity 
receptor site", J Biol Chem 278: 24808-24817 (2003a) and 
Lad, S. P. et al., "Nerve growth factor: structure, function 
and therapeutic implications for Alzheimer's disease", Curr 
Drug Targets CNS Neural Disord 2: 315-334 (2003b)). 
10 Identifying neurotrophic factors with the right combination 
of protective and restorative actions and developing effec-
tive strategies for drug delivery have profound therapeutic 
implications for Parkinson's disease, Alzheimer's disease, 
Huntington's disease and other degenerative processes in the 
15 brain (including those induced by brain injury). 
Glial cell line-derived neurotrophic factor (GDNF) is a 
trophic factor shown to dramatically protect and enhance the 
function of dopamine neurons in vitro and in vivo in rodents 
and monkeys (Beck, K. D., et al., "Mesencephalic dopamin-
20 ergic neurons protected by GDNF from axotomy-induced 
degeneration in the adult brain", Nature, 373:339-41 
(1995); and Bjorklund, A., et al., "Towards a neuroprotective 
gene therapy for Parkinson's disease: use of adenovirus, 
AAV and lentivirus vectors for gene transfer of GDNF to the 
25 nigrostriatal system in the rat Parkinson model", Brain 
Res., 886:82-98 (2000), Gash, D. M., et al., "Functional 
Recovery in Parkinsonian Monkeys Treated with GDNF, 
Nature", 380:252-255 (1996); Grondin, R., et al., "Striatal 
GDNF Infusion Promotes Structural and Functional Recov-
30 ery in Advanced Parkinsonian Monkeys. Brain", 125:2191-
2201 (2002); Grondin, R., et al., "GDNF Increases Stimulus-
evoked Dopamine Release and Motor Speed in Aged Rhesus 
Monkeys", J. Neurosci., 23:1974-1980 (2003); Hebert M. 
A., et al., "Functional Effects of GDNF in Normal Rat 
35 Striatum: Presynaptic Studies Using In Vivo Electrochem-
istry and Microdialysis", J. Pharm. Exp. Ther., 279:1181-
1190 (1996); Hebert M.A. and Gerhardt, G. A., "Behavioral 
and Neurochemical Effects of Intranigral GDNF Adminis-
tration on Aged Fischer 344 Rats", J. Pharm. Exp. Ther., 
40 282: 760-768 (1997); Hou, J. G. G., et al., "Glial Cell 
line-Derived Neurotrophic Factor Exerts Neurotrophic 
Effects on Dopaminergic Neurons In Vitro and Promotes 
Their Survival And Regrowth After Damage by l-Methyl-4-
Phenylpyridinium ", J. Neurochem., 66: 74-82 (1996); Kor-
45 dower, J. H., et al., "Clinicopathological Findings Follow-
ing Intraventricular Glial-Derived Neurotrophic Factor 
Treatment in a Patient with Parkinson's Disease", Ann 
Neural., 46(3):419-424 (1999); Kordower, J. H., et al., 
"Neurodegeneration Prevented by Lentiviral Vector Deliv-
50 ery of GDNF in Primate Models of Parkinson's Disease", 
Science, 290: 767-773 (2000); Palfi, S., et al., "Lentivirally 
Delivered Glial Cell Line-derived Neurotrophic Factor 
Increases the Number of Striatal Dopaminergic Neurons in 
Primate Models of Nigrostriatal Degeneration", J. Neuro-
55 sci., 22:4942-4954 (2002); Tomac, A., et al., "Protection and 
Repair of the Nigrostriatal Dopaminergic System by GDNF 
In Vivo", Nature, 373:335-339 (1995)). 
The current standard treatment, levodopa, is palliative and 
does not prevent the relentless progression of Parkinson's 
60 degeneration. GDNF exerts effects on dopamine neurons 
that slow the process of Parkinson's disease and even 
reverses some of the degenerative changes. Preclinical stud-
ies conducted to date suggest that GDNF exerts at least three 
general trophic actions on dopamine neurons in the substan-
65 tia nigra: pharmacological upregulation, restoration and 
neuroprotection. With regard to pharmacological upregula-
tion, GDNF upregulates dopaminergic functions, such as 
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increasing the evoked release of dopamine (Gerhardt, G. A. 
et al., "GDNF improves dopamine function in the substantia 
nigra but not the putamen of unilateral MPTP-lesioned 
rhesus monkeys", Brain Res 817: 163-171 (1999) and Gron-
din et al., 2003). It also appears to modulate the phospho-
rylation of TH (Salvatore, M. et al. "Striatal GDNF admin-
istration increases tyrosine hydroxylase phosphorylation in 
the rat striatum and substantia nigra". J Neurochem. 90:245-
54, (2004)). With regard to restoration, GDNF increases the 
number of neurons expressing the dopamine markers TH 10 
and DAT in the substantia nigra (Gash et al., 1996; Kor-
dower et al., 2000; and Grondin et al., 2002). This suggests 
that one trophic action is to stimulate recovery of injured/ 
quiescent nigral neurons. Supporting this interpretation is 
the consistent observation that GDNF promotes increases in 15 
dopamine neuron perikaryal size and the number of neurites. 
With regard to neuroprotection, nigrostriatal administration 
of GDNF either shortly before or following a neurotoxic 
challenge (e.g. 6-0HDA, methyl-amphetamine or MPTP) 
protects dopamine neurons from injury in rodents and non- 20 
human primates (Kordower et al., 2000 and Fox, C. M., 
"Neuroprotective effects of GDNF against 6-0HDA in 
young and aged rats", Brain Res 896:56-63 (2001)). 
Accordingly, GDNF therapy is expected to be helpful in 
the treatment of nerve damage caused by conditions that 25 
compromise the survival and/or proper function of one or 
more types of nerve cells. Such nerve damage may occur 
from a wide variety of different causes. Nerve damage may 
occur to one or more types of nerve cells by, for example: (1) 
physical injury, which causes the degeneration of the axonal 30 
processes and/or nerve cell bodies near the site of injury; (2) 
temporary or permanent cessation of blood flow to parts of 
the nervous system, as in stroke; (3) intentional or accidental 
exposure to neurotoxins, such as chemotherapeutic agents 
(e.g., cisplatinum) for the treatment of cancer or dideoxy- 35 
cytidine (ddC) for the treatment of AIDS; (4) chronic 
metabolic diseases, such as diabetes or renal dysfunction; or 
(5) neurodegenerative diseases such as Parkinson's disease, 
Alzheimer's disease, and Amyotrophic Lateral Sclerosis 
(ALS), which result from the degeneration of specific neu- 40 
ronal populations. 
GDNF therapy may be particularly helpful in the treat-
ment of neurodegenerative conditions involving the degen-
eration of the dopaminergic neurons of the substantia nigra, 
such as Parkinson's disease. The expected impact ofGDNF 45 
therapy is not just to produce an increase in the dopamin-
ergic neurotransmission at the dopaminergic nerve terminals 
in the striatum (which will result in a relief of the symp-
toms), but also to slow down, or even stop, the progression 
of the degenerative processes and to repair the damaged 50 
nigrostriatal pathway and restore its function. GDNF may 
also be used in treating other forms of damage to or 
improper function of dopaminergic nerve cells in human 
subjects. Such damage or malfunction may occur in schizo-
phrenia and other forms of psychosis. The only current 55 
treatments for such conditions are symptomatic and require 
drugs which act upon dopamine receptors or dopamine 
uptake sites, consistent with the view that the improper 
functioning of the dopaminergic neurons which innervate 
these receptor-bearing neuronal populations may be 60 
involved in the disease process. 
However, initial clinical trials involving ventricular deliv-
ery of GDNF showed no statistically significant differentia-
tion of the placebo and active treatment groups (Nutt, J. G. 
et al. "Randomized, double-blind trial of glial cell line- 65 
derived neurotrophic factor ( GDNF) in PD", Neurology 60: 
69-73 (2003)), perhaps because insufficient amounts of 
4 
GDNF reached critical target sites from the CSF (Ai, Y. et 
al., "Intraputamenal Infusion in Aging Rhesus Monkeys: 
Distribution and Dopaminergic Effects", J Comp Neural 
461: 250-26125 (2003); and Kordower, J. H., et al. (2000)). 
In addition, a phase 2 trial evaluating intraputamenal deliv-
ery of glial cell line-derived neurotrophic factor (GDNF) for 
the treatment of Parkinson's disease failed to achieve its 
primary end point, a 25% improvement on the Unified 
Parkinson Disease Rating Scale (UPDRS) motor score "off' 
medication after six months of treatment (Lang, A. E. et al., 
"Randomized controlled trial of intraputamenal glial cell 
line-derived neurotrophic factor infusion in Parkinson's 
disease", Ann Neural 59:459-466 (2006)). There are strong 
indications from studies in rhesus monkeys using the same 
delivery system and protocol followed in the phase 2 study 
that drug bioavailability significantly contributed to the 
failure of the trial (Salvatore et al., "Point source concen-
tration of GDNF may explain failure of phase II clinical 
trial". Exp Neural 202 (2): 497-505 (2006)). The concen-
tration of GDNF around the catheter tip and limited diffusion 
into surrounding brain parenchyma was limited to a brain 
volume representing 2-9% of the human putamen. Thus 
GDNF distribution in the phase 2 trial was likely limited to 
a small brain region, and could affect only a limited segment 
of the brain undergoing parkinsonian degeneration. 
Successful trophic factor therapy requires site-specific 
delivery and distribution of the trophic factor throughout the 
target tissue (the putamen for Parkinson's disease). The 
blood brain barrier effectively blocks entry from blood borne 
proteins, including trophic factors. Infusions into the cere-
brospinal fluid are not effective in humans because of brain 
size and may produce unwanted side effects by stimulating 
other trophic factor responsive populations such as sensory 
neurons. 
In addition to focal delivery into the appropriate site, the 
delivery must be tightly regulated. Regardless of the method 
used to deliver GDNF (i.e., direct infusion, stem cells, 
encapsulated cells, gene therapy) prolonged elevated levels 
of GDNF in the brain outside of the target area may produce 
adverse side-effects. Circulating antibodies to GDNF are 
one possible outcome and it is quite typical to find antibodies 
to endogenous proteins used therapeutically (e.g. beta inter-
feron and insulin, see Durelli, L., et al., "Anti-interferon 
antibodies in multiple sclerosis: molecular basis and their 
impact on clinical efficacy", Front Biosci 9: 2192-2204 
(2004) and Stoever, J. A. et al., "Inhaled insulin and insulin 
antibodies: a new twist to an old debate", Diabetes Technol 
Ther 4: 157-161 (2002)). The effects of circulating GDNF 
antibodies are not known. Focal Purkinje cell lesions have 
been reported in some monkeys receiving high levels of 
GDNF in a toxicology study (see Sherer, T. B., et al., 
Movement Dis 21:136-141 (2006)). Another possible side-
effect is aberrant sprouting and tyrosine hydroxylase down-
regulation of the nigrostriatal dopaminergic pathway in rats 
exposed to high GDNF levels from viral vector gene transfer 
(Georgievska, B., et al. "Neuroprotection in the rat Parkin-
son model by intrastriatal GDNF gene transfer using a 
lentiviral vector", Neuroreport 13: 75-82 (2002)). Also, 
increased neuronal death has been reported in rats with 
elevated GDNF from viral vector gene transfer in a stroke 
model (Arvidsson, A. et al., "Elevated GDNF levels follow-
ing viral vector-mediated gene transfer can increase neu-
ronal death after stroke in rats", Neurobiol Dis 14: 542-556, 
(2003)). 
While GDNF has not met the criteria for clinical efficacy 
in the two phase 2 trials conducted to date (Nutt et al., 2003; 
Lang et al., 2006), it appears to be the most potent dop-
US 9,586,992 B2 
5 
aminergic trophic factor found to date. Thus, the ideal drug 
for treating Parkinson's disease and other neurodegenerative 
processes in the brain would possess the positive trophic 
actions of GDNF. Delivery could be targeted to the appro-
priate brain area by any of a number of methods including 5 
direct infusion, viral vectors or even nasal sprays. In par-
ticular, biologically active peptides with trophic actions may 
offer many of the desired properties. To date, such biologi-
cally active peptides have not been identified. 
A crude peptide extract from the brain cerebrolysin has 10 
been tested in human studies, with modest effects reported 
(Lukhanina, E. P. et al., "Effect of cerebrolysin on the 
electroencephalographic indices of brain activity in Parkin-
son's disease", Zh Nevrol Psikhiatr Im SS Korsakova 104: 
54-60 (2004)). Three small molecule compounds have also 15 
been tested in Parkinson's disease patients: the tripeptide 
glutathione, tocopherol, and Coenzyme QlO (Weber, C. A., 
et al. "Antioxidants, supplements and Parkinson's disease", 
Ann Pharmacother 40: 935-938 (2006)). The three small 
molecule compounds also appear to have only minor ben- 20 
efits for patients. 
Consequently, there continues to exist a long-felt need for 
effective agents and methods for the treatment and preven-
tion of brain diseases and injuries that result in dopaminergic 
deficiencies. Accordingly, it is an object of the present 25 
invention to provide agents for treating and preventing such 
diseases and injuries in a subject, comprising novel ami-
dated GDNF-derived peptides that have dopaminergic 
trophic factor activity. This and other such objectives will be 
readily apparent to the skilled artisan from this disclosure. 30 
SUMMARY OF THE INVENTION 
In one embodiment, the present invention provides a 
composition comprising at least one of the following pep- 35 
tides: (a) a purifiedAmidated Dopamine Neuron Stimulating 
peptide (ADNS peptide) comprising the amino acid 
sequence ERNRQAAAANPENSRGK-amide (SEQ ID NO: 
2); (b) a purified ADNS peptide comprising the amino acid 
sequence FPLPA-amide (SEQ ID NO: 3); and (c) a purified 40 
ADNS peptide comprising the amino acid sequence PPEA-
PAEDRSL-amide (SEQ ID NO: 4). In another embodiment, 
the present invention provides a method for treating a brain 
disease or injury resulting in dopaminergic deficiencies, 
comprising administering a pharmaceutically effective 45 
amount of the composition to a subject in need thereof, 
wherein said composition further comprises at least one of 
a pharmaceutically acceptable vehicle, excipient, and 
diluent. Preferably, the subject is a mammal, and most 
preferably, the subject is human. 50 
6 
FIG. 4 depicts the average K+-evoked release of dop-
amine in Fischer 344 rats treated with ADNS peptides. 
FIG. 5 depicts the increase in major metabolites of 
dopamine in Fischer 344 rats treated with ADNS peptides. 
FIG. 6 depicts the increased survival of dopamine neurons 
in cell cultures treated with ADNS peptides. 
FIGS. 7 A and B depict the results of in vivo microdialysis 
used to investigate the dynamics of dopamine release in the 
basal ganglia of the right putamen following treatment with 
ADNS peptides. 
FIGS. SA-F depict the histopathological response to the 
injection of ADNS peptides in the nigral region using 
standard histochemical techniques. 
FIGS. 9A-D depict a series of photomicrographs evalu-
ating the substantia nigra compacta (SNc) containing the 
population of dopamine neurons that degenerates in Parkin-
son's disease after treatment with ADNS peptides. 
FIGS. lOA and B depict the sequence origin and homol-
ogy of dopamine neuron stimulating peptide-11 (DNSP-11 ). 
FIGS. llA-D depict the neurotropic effects of DNSP-11 
and GDNF on mesencephalic (A and B) and MN9D (C and 
D) dopaminergic cells. 
FIGS. 12A-C depict the effects ofDNSP-11 in normal (A) 
and unilateral 6-0HDA-lesioned (B and C) rats. 
FIG. 13 depicts the interactions of DNSP-11 with protein 
partners. 
FIG. 14 depicts the gel filtration analysis of the interaction 
between GAPDH and GDNF. 
FIGS. 15A-C depict the solubility and stability ofDNSP-
11 at various storage and experimental conditions. 
FIG. 16 shows the effects of citrate vehicle or DNSP-11 
on resting levels of DOPAC one month after a single 
infusion. 
FIG. 17 shows the broad distribution of DNSP-11 in the 
rat substantia nigra region of the midbran within 30 minutes 
of DNSP-11 injection (panels A-F). 
FIG. 18 shows the DNSP-11 increased State III oxygen 
consumption vs. vehicle in both the SN and striatum, 28 
days post bilateral intrnigral injections (*p<0.05 vs control, 
two-tailed, unpaired tests). (A) Substantia nigra 28 days; (B) 
Striatum 28 days. 
FIG. 19 demonstrates that DNSP-11 produced a signifi-
cant, about 50%, decrease in apomorphine-induced rota-
tional behavior (A) and significantly increased levels of 
dopamine and the dopamine metabolite, DOPAC, by about 
100% in the substantia nigra (B). 
DETAILED DESCRIPTION OF THE 
INVENTION 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 depicts the nucleotide sequence (top strand) and 
amino acid sequence (bottom strand) of mature human 
GDNF (SEQ ID NO: 5 and SEQ ID NO: 1). 
Human glial cell line-derived neurotrophic factor 
(hGDNF) is synthesized as a precursor that is processed and 
secreted as a mature protein of 134 amino acids. Mature 
55 human GDNF has the amino acid sequence depicted in FIG. 
1 (SEQ ID NO: 1 ). 
FIG. 2 depicts the post-translational processing of splice 
form 1 of human GDNF. Sequences from top to bottom are: 
SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 
9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ 
ID NO: 13, SEQ ID NO: 3, SEQ ID N0:4, and SEQ ID NO: 
2. 
FIG. 3 depicts the precursor segments of the ADNS 
peptides ERNRQAAAANPENSRGK-amide (SEQ ID NO: 
2), FPLPA-amide (SEQ ID N0:3), and PPEAPAEDRSL-
amide (SEQ ID N0:4). From top to bottom SEQ ID NO: 8, 
SEQ ID NO: 14, and SEQ ID N0:15. 
The present invention is related to the realization that 
human GDNF (splice form 1) precursor protein conforms to 
a rather exacting sequence profile characteristic of neuro-
60 peptide precursor proteins. GDNF is expressed in at least 
three isoforms that result from alternative splicing of 
mRNA. Proteins expressed from these RNA splice variants 
differ in their N-terminal regions (see NCBI entry NP 
000505 for isoform 1; NCBI entry NP 964701 for isoform 
65 2; and NCBI entry NP 954704 for isoform 3). Isoforms 1 and 
2 are secretory protein precursors with N-terminal signal 
peptides. Isoform 3 is likely a nuclear-targeted protein with 
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a nuclear localization signal (NLS), but no signal peptide. 
The three isoforms are differentially expressed, apparently 
under regulatory control. 
All of the isoforms contain the sequence that is considered 
mature GDNF with "full biological activity" (residues 
78-211 in isoform 1). In fact, recombinant proteins further 
truncated at the N-terminus are purported to have the "full 
biological activity". From the fact that three separate pre-
cursors of the same GDNF molecule are expressed under 
separate regulation, two with signal peptides and the third 
with a probable nuclear localization signal, suggests that 
there are both nuclear and cell surface receptors for GDNF. 
8 
gests a reason for differential expression of three separate 
isoforms (in addition to differential secretory and nuclear 
routing). 
According to this model, splice form 1 of human GDNF 
may be post-translationally processed in vivo to yield three 
small amidated peptides, as indicated in FIG. 2. These small 
amidated peptides may mediate some or all of the biological 
effects of GDNF. The present invention is based on the 
unexpected discovery that these small amidated fragments 
10 of the mature GDNF protein retain the biological activity of 
GDNF. 
Thus, the ADNS peptides of the present invention include 
The separately regulated expression of two different 
secretory isoforms (isoforms 1 and 2) suggests a biologically 
significant function for the different N-terminal sequences of 15 
the isoforms. The conventional wisdom is that residues 
these three small amidated peptides, which are represented 
by the amino acid sequences ERNRQAAAANPENSRGK-
amide; FPLPA-amide; and PPEAPAEDRSL-amide (SEQ ID 
NOs:2, 3, and 4, respectively). 
20-77 of isoform 1 precursor constitute a "domain propep-
tide". The present invention provides a new interpretation of 
the importance of the 20-77 "domain propeptide" region of 
isoform 1 precursor. The "domain propeptide" segment of 
isoform 1 precursor is the metabolic precursor of two small 
amidated peptides, according to well established enzymatic 
pathways for release of peptide amide hormones and neu-
ropeptides from their precursor proteins. The two small 
amidated peptides are FPLPA-amide (SEQ ID NO: 3) and 
PPEAPAEDRSL-amide (SEQ ID NO: 4). 
Furthermore, a third small amidated peptide, ERN-
RQAAAANPENSRGK-amide (SEQ ID NO: 2), may be 
released from consensus enzymatic processing of residues 
88-110 of the isoform 1 precursor. This consensus peptide 
amide precursor occupies the N-terminal sequence of 
"mature GDNF", which is presumably not critical or at least 
includes residues that are not critical for biological activity, 
according to the patent literature. The isoform 2 precursor 
contains the sequence FPLPA (SEQ ID NO: 16), but does 
not contain the amidation signal (GKR, residues 25-27) in 
the case of Isoform 1 precursor. Isoform 2 is not, in other 
words, a potential precursor ofFPLPA-amide (SEQ ID NO: 
3) according to known enzymatic pathways. Isoform 3 does 
not contain the sequence FPLPA at all, so likewise can not 
be a metabolic precursor ofFPLPA-amide (SEQ ID NO: 3). 
Both Isoforms 1 and 2 are consensus precursors of ERN-
RQAAAANPENSRGK-amide (SEQ ID NO: 2), but isoform 
3 is not. 
Thus, human GDNF isoform 1 is a secretory protein that 
can potentially yield three small amidated peptides by 
consensus enzymatic pathways known to release peptide 
amide hormones and neuropeptides from their known pre-
cursor proteins. This is a rare combination of enzymatic 
processing motifs and strongly suggests that GDNF isoform 
1 precursor is the metabolic precursor of up to three small 
ADNS peptides, in addition to the larger C-terminal domain 
that is widely supposed to posses the "full biological activ-
ity" of GDNF. C-terminal amidation in natural peptides is 
highly correlated with receptor mediated signal transduc-
tion: about half of the known peptide hormones and neuro-
peptides and C-terminal amidation is rare and almost 
unknown among other peptides of biological origin. 
Animal studies with synthetic peptides corresponding to 
the consensus products of Isoform 1 precursor protein are 
consistent with some or all of these peptides being biologi-
cally active and involved in regulation of dopamine metabo-
lism. This is to be expected from a protein that yields 
multiple biologically active regulatory peptides in a fixed 
molar ratio. The fact that the different Isoforms of GDNF 
precursor protein are consensus precursors of different com-
binations of amidated peptides in addition to GDNF, sug-
The ADNS peptides of the present invention are promis-
ing candidates for treatment and prevention of neurodegen-
erative conditions involving dopaminergic deficiencies, such 
20 as Parkinsons disease, age-associated motor and cognitive 
slowing, and other diseases and injuries to the brain. The 
small ADNS peptides are easily within the range of synthetic 
production methods, so that the molecules could be sub-
jected to rigorous structure-activity studies to optimize phar-
25 macological activities and biostability. In addition, as the 
difficulties in delivering GDNF clinically may well be 
related to the fact that recombinant GDNF is not properly 
processed into active forms, the small ADNS peptides may 
overcome some of these difficulties. Finally, small peptides 
30 are generally much less antigenic than proteins and can be 
synthesized free of the trace host protein contaminants 
always present in recombinant proteins. 
The small ADNS peptides of the present invention include 
biologically active synthetic or recombinant ADNS pep-
35 tides, ADNS peptides produced from GDNF, biologically 
active ADNS peptide variants (including insertion, substi-
tution, and deletion variants), and chemically modified 
derivatives thereof. Also included are biologically active 
ADNS peptide variants that are substantially homologous to 
40 any one of the ADNS peptides having the amino acid 
sequence set forth in SEQ ID NOs:2, 3, or 4. 
The term "biologically active" as used herein means that 
the ADNS peptide demonstrates similar neurotrophic prop-
erties, but not necessarily all of the same properties, and not 
45 necessarily to the same degree, as the GDNF protein having 
the amino acid sequence set forth in SEQ ID NO: 1. The 
selection of the particular neurotrophic properties of interest 
depends upon the use for which the ADNS peptide is being 
administered. The ADNS peptides are biologically active 
50 and demonstrate dopaminergic neuron survival characteris-
tics similar to that demonstrated by the combination of 
amide peptides represented by SEQ ID NOs:2, 3, or 4 using 
the evaluation of dopamine neuron survival in cultures of 
newborn rat midbrain dopamine neurons as an exemplary 
55 bioassay, as discussed in the examples below. 
The term "substantially homologous", as used herein, 
means a degree of sequence homology to any one of the 
ADNS peptides having the amino acid sequences set forth in 
SEQ ID NOs:2, 3, or 4 that is preferably at least 70%, most 
60 preferably at least 80%, and even more preferably at least 
90% or even 95%. 
As used herein, the term "ADNS peptide," "peptide 
amide," or "amidated peptide" means a peptide comprising 
the group -CONH2 at the C-terminal end. This amidation 
65 occurs in vivo, once the peptides are formed by the enzyme, 
peptidylglycine amidating monooxygenase (PAM). The 
ADNS peptides of the present invention can be readily 
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obtained in a variety of ways, including, without limitation, 
recombinant expression, purification from natural sources, 
and/or chemical synthesis. Preferably, the ADNS peptides 
can be chemically synthesized by commercial venders. The 
ADNS peptides used in the present examples were synthe-
sized using tBOC chemistry and at a single scale range 
(which generates a theoretical crude yield of 500-1,000 mg 
for a 10-20 mer respectively), by the Keck Biotechnology 
Resource Laboratory at Yale University (New Haven, 
Conn.). 
ADNS peptide pharmaceutical compositions typically 
include a therapeutically effective amount of at least one of 
a ADNS peptide represented by SEQ ID NOs:2, 3, and 4 in 
admixture with one or more pharmaceutically and physi-
ologically acceptable formulation materials. Suitable formu-
lation materials include, but are not limited to, antioxidants, 
preservatives, coloring, flavoring and diluting agents, emul-
sifying agents, suspending agents, solvents, fillers, bulking 
agents, buffers, delivery vehicles, diluents, excipients and/or 
pharmaceutical adjuvants. For example, a suitable vehicle 
may be water for injection, physiological saline solution, or 
artificial cerebrospinal fluid (CSF), possibly supplemented 
with other materials common in compositions for parenteral 
administration. Neutral buffered saline or saline mixed with 
serum albumin are further exemplary vehicles. 
The primary solvent in a vehicle may be either aqueous or 
non-aqueous in nature. In addition, the vehicle may contain 
other pharmaceutically-acceptable excipients for modifying 
or maintaining the pH, osmolarity, viscosity, clarity, color, 
sterility, stability, rate of dissolution, or odor of the formu-
lation. Similarly, the vehicle may contain still other phar-
maceutically-acceptable excipients for modifying or main-
taining the stability, rate of dissolution, or rate of release of 
ADNS peptide, or for promoting the absorption or penetra-
tion of ADNS peptide across the blood-brain barrier. Such 
excipients are those substances usually and customarily 
employed to formulate dosages for parenteral administration 
in either unit dose or multi-dose form or for direct infusion 
into the CSF by continuous or periodic infusion from an 
implanted pump. 
Once the therapeutic composition has been formulated, it 
may be stored in sterile vials as a solution, suspension, gel, 
emulsion, solid, or dehydrated or lyophilized powder. Such 
formulations may be stored either in a ready to use form or 
in a form, e.g., lyophilized, requiring reconstitution prior to 
administration. 
10 
peptide in a pharmaceutically acceptable vehicle. One pre-
ferred vehicle is physiological saline. 
It is also contemplated that certain formulations contain-
ing ADNS peptides are to be administered orally. ADNS 
peptide which is administered in this fashion may be encap-
sulated and may be formulated with or without those carriers 
customarily used in the compounding of solid dosage forms. 
The capsule may designed to release the active portion of the 
formulation at the point in the gastrointestinal tract when 
10 bioavailability is maximized and pre-systemic degradation 
is minimized. Additional excipients may be included to 
facilitate absorption of ADNS peptide. 
Diluents, flavorings, low melting point waxes, vegetable 
oils, lubricants, suspending agents, tablet disintegrating 
15 agents, and binders may also be employed. 
It is further contemplated that formulations containing 
ADNS peptides are to be administered nasally. As used 
herein, nasally administering or nasal administration 
includes administering the formulation containing ADNS to 
20 the mucous membranes of the nasal passage or nasal cavity 
of the patient. Formulations for nasal administration include 
a pharmaceutically effective amount of the peptides pre-
pared by well-known methods, to be administered, for 
example, as a nasal spray, drop, suspension, gel, ointment, 
25 cream or powder. Administration of the ADNS-containing 
formulation may also take place using a nasal tampon, or 
nasal sponge. 
The ADNS peptides may be administered parenterally via 
a subcutaneous, intramuscular, intravenous, transpulmonary, 
30 transdermal, intrathecal or intracerebral route. ADNS pep-
tides that do not cross the blood-brain barrier may be given 
directly intracerebrally or otherwise in association with 
other elements that will transport them across the barrier. It 
is preferred that the ADNS peptide is administered intrac-
35 erebroventricularly or into the brain or spinal cord suba-
rachnoid space. ADNS peptides may also be administered 
intracerebrally directly into the brain parenchyma. Slow-
releasing implants in the brain containing the neurotrophic 
factor embedded in a biodegradable polymer matrix can also 
40 deliver ADNS peptides. ADNS peptides may be adminis-
tered extracerebrally in a form that has been modified 
chemically or packaged so that it passes the blood-brain 
barrier, or it may be administered in connection with one or 
more agents capable of promoting penetration ADNS pep-
45 tide across the barrier. For example, a conjugate ofNGF and 
monoclonal anti-transferrin receptor antibodies has been 
shown to be transported to the brain via binding to trans-
ferrin receptors. To achieve the desired dose of ADNS 
peptide, repeated daily or less frequent injections may be 
The optimal pharmaceutical formulation will be deter-
mined by one skilled in the art depending upon the route of 
administration and desired dosage. See for example, Rem-
ington's Pharmaceutical Sciences, 18th Ed. (1990, Mack 
Publishing Co., Easton, Pa. 18042) pages 1435-1712 the 
disclosure of which is hereby incorporated by reference. The 
composition may also involve particulate preparations of 
polymeric compounds such as polylactic acid, polyglycolic 
acid, etc. or into liposomes. Hylauronic acid may also be 55 
used, and this may have the effect of promoting sustained 
duration in the circulation. Such compositions may influence 
the physical state, stability, rate of in vivo release, and rate 
50 administered, or truncated ADNS peptide may be infused 
continuously or periodically from a constant- or program-
mable-flow implanted pump. The frequency of dosing will 
depend on the pharmacokinetic parameters of ADNS peptide 
as formulated, and the route of administration. 
Regardless of the manner of administration, the specific 
dose is typically calculated according to body weight or 
body surface area. For diseases involving the brain, the 
specific dose is typically calculated according to the 
approximate brain weight of the subject, which also may be of in vivo clearance of the present proteins and derivatives. 
Other effective administration forms, such as parenteral 
slow-release formulations, inhalant mists, orally active for-
mulations, or suppositories, are also envisioned. Preferred 
ADNS peptide pharmaceutical compositions are formulated 
for parenteral administration, e.g., intracerebroventricular 
injection. Such parenterally administered therapeutic com-
positions are typically in the form of a pyrogen-free, par-
enterally acceptable aqueous solution comprising ADNS 
60 estimated based on body weight or body surface area. 
Further refinement of the calculations necessary to deter-
mine the appropriate dosage for treatment involving each of 
the above mentioned formulations is routinely made by 
those of ordinary skill in the art, especially in light of the 
65 dosage information and assays disclosed herein. Appropriate 
dosages may be ascertained through use of the established 
assays for determining dosages utilized in conjunction with 
US 9,586,992 B2 
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appropriate dose-response data. The final dosage regimen 
involved in a method of treating a specific condition will be 
determined by the attending physician, considering various 
factors which modify the action of drugs, e.g., the age, 
condition, body weight, sex and diet of the subject, the 
severity of any infection, time of administration and other 
clinical factors. 
12 
Implanted cells may be encapsulated to avoid infiltration 
of the cells into brain tissue. Human or non-human animal 
cells may be implanted in subjects in biocompatible, semi-
permeable polymeric enclosures or membranes to allow 
release of an ADNS peptide, but that prevent destruction of 
the cells by the subject's immune system or by other 
detrimental factors from the surrounding tissue. Alterna-
tively, the subject's own cells, transformed ex vivo to 
produce ADNS peptides, could be implanted directly into 
ADNS peptides of the present invention may also be 
employed, alone or in combination with other growth factors 
in the treatment of nerve disease. For example, ADNS 
peptides may be used in treating some forms of nerve 
disease in combination with nerve growth factor. In addition, 
other factors or other molecules, including chemical com-
positions, may be employed together with ADNS peptides. 
In the treatment of Parkinson's disease, it is contemplated 
that ADNS peptide be used by itself or in conjunction with 
the administration of Levodopa, wherein the ADNS peptide 
would enhance the production of endogenous dopamine and 
the neuronal uptake of the increased concentration of dop-
amme. 
10 the subject without such encapsulation. 
The methodology for the membrane encapsulation of 
living cells is familiar to those of ordinary skill in the art, and 
the preparation of the encapsulated cells and their implan-
tation in subjects may be accomplished. See for example, 
15 U.S. Pat. Nos. 4,892,538; 5,011,472; and 5,106,627, the 
disclosures of which are hereby incorporated by reference. 
A system for encapsulating living cells is also described in 
PCT Application WO 91/10425 of Aebischer et al., specifi-
cally incorporated herein by reference. See also, PCT Appli-
20 cation WO 91/10470 of Aebischer et al.; Winn et al., Exper. 
As stated above, it is also contemplated that additional 
neurotrophic or neuron nurturing factors will be useful or 
necessary to treat some neuronal cell populations or some 
types of injury or disease. Other factors that may be used in 25 
conjunction withADNS peptides include, but are not limited 
Neural., 113:322-329, 1991; Aebischer et al., Exper. Neural., 
111:269-275, 1991; and 35 Tresca et al., ASAIO, 38:17-23, 
1992, the disclosures of which are hereby incorporated by 
reference. 
ADNS peptide gene therapy in vivo is also envisioned, 
wherein a nucleic acid sequence encoding anADNS peptide 
is introduced directly into the subject. For example, a 
nucleic acid sequence encoding an ADNS peptide is intro-
duced into target cells via local injection of a nucleic acid 
30 construct with or without an appropriate delivery vector, 
such as an adeno-associated viral vector. Alternative viral 
to: mitogens such as insulin, insulin-like growth factors, 
epidermal growth factor, vasoactive growth factor, pituitary 
adenylate cyclase activating polypeptide, interferon and 
somatostatin; neurotrophic factors such as brain derived 
neurotrophic factor, neurotrophin-3, neurotrophin-4/5, neu-
rotrophin-6, insulin-like growth factor, ciliary neurotrophic 
factor, acidic and basic fibroblast growth factors, fibroblast 
growth factor-5, transforming growth factor-.beta., cocaine-
amphetamine regulated transcript (CART) and mature 35 
GDNF; and other growth factors such as epidermal growth 
factor, leukemia inhibitory factor, interleukins, interferon, 
and colony stimulating factors; as well as molecules and 
materials which are the functional equivalents to these 
factors. 
vectors include, but are not limited to, retrovirus, adenovi-
rus, herpes simplex virus and papilloma virus vectors. 
Physical transfer may be achieved in vivo by local injection 
of the desired nucleic acid construct or other appropriate 
delivery vector containing the desired nucleic acid sequence, 
liposome-mediated transfer, direct injection (naked DNA), 
receptor-mediated transfer (ligand-DNA complex), or 
microparticle bombardment (gene gun). It should be noted 
It is envisioned that the continuous administration or 
sustained delivery of a ADNS peptide may be advantageous 
for a given treatment. While continuous administration may 
40 that the ADNS peptide formulations described herein may 
be used for veterinary as well as human applications and that 
the term "subject" should not be construed in a limiting 
manner. In the case of veterinary applications, the dosage 
be accomplished via a mechanical means, such as with an 
infusion pump, it is contemplated that other modes of 45 
continuous or near continuous administration may be prac-
ticed. For example, chemical derivatization may result in 
sustained release forms of the protein which have the effect 
ranges should be the same as specified above. 
As a means of further characterizing the ADNS peptides 
of the present invention, antibodies can be developed which 
bind to the ADNS peptides. One of ordinary skill in the art 
can use well-known, published procedures to obtain mono-
clonal and polyclonal antibodies, or recombinant antibodies, of continuous presence in the blood stream, in predictable 
amounts, based on a determined dosage regimen. Thus, 
ADNS peptides of the present invention include ADNS 
peptides derivatized to effectuate such continuous adminis-
tration. 
50 which specifically recognize and bind to the various ADNS 
peptides of the present invention. 
Other aspects and advantages of the present invention will 
be understood upon consideration of the following illustra-
tive examples. The examples are not to be construed in any 
55 way as limiting the scope of this invention. 
ADNS peptide cell therapy, e.g., intracerebral implanta-
tion of cells producing ADNS peptides, is also contem-
plated. This embodiment of the present invention may 
include implanting into subject's cells which are capable of 
synthesizing and secreting a biologically active form of the 
ADNS peptides of the present invention. Such ADNS pep-
tide producing-cells may be cells which do not normally 60 
produce a neurotrophic factor but have been modified to 
produce ADNS peptides, or they could be cells whose ability 
to produce GDNF has been augmented by transformation 
with a polynucleotide suitable for the expression and secre-
tion of ADNS peptides. In order to minimize a potential 65 
immunological reaction in subjects, it is preferred that the 
cells be of human origin. 
EXAMPLES 
Example 1 
BLAST Analysis 
The three hypothetical precursor segments (RRERN-
RQAAAANPENSRGKGRR (SEQ ID NO: 5); FPLPAGKR 
(SEQ ID NO: 8); and KRPPEAPAEDRSLGRR (SEQ ID 
NO: 7); see FIG. 3) were subjected to BLAST searches for 
short, nearly identical sequences. RRERNRQAAAANPEN-
US 9,586,992 B2 
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SRGKGRR (SEQ ID NO: 15) is present in GDNF splice 
forms 1 and 2. There are some sequence variations by 
species, but consensus post-translational processing signals 
are maintained across species. FPLPAGKR (SEQ ID NO: 8) 
was found to be invariant in the available GDNF splice form 5 
1 sequences, but does not occur in splice forms 2 and 3. 
KRPPEAPAEDRSLGRR (SEQ ID NO: 7) scored hits in 
splice form 1, but not in the other GDNF splice forms. There 
are some sequence variations by species, but consensus 
processing signals are maintained across species. Thus, 10 
these ADNS peptides are unique to mostly splice form 1 of 
GDNF and not other splice forms of the pre pro GDNF. 
Example 2 
15 
Synthesis of ADNS Peptides 
14 
amine increased by over 50% (FIG. 4). Average amphet-
amine-evoked release was more variable, but ranged from 
about 30% for 100 µg to about 45% for 30 µg. While basal 
dopamine levels were about the same in all three groups, 
basal metabolite levels were elevated. As shown in FIG. 5, 
the major metabolites 3,4-Dihydroxy-Phenylacetic Acid 
(DOPAC) and Homovanillic Acid (HVA) were increased by 
about 40% (DOPAC) and 20-40% (HVA), depending upon 
the dose. 
Example 4 
Dopaminergic Activity of ADNS Peptides in Cell 
Cultures of Rat Midbrain Dopamine Neurons 
To further characterize the bioactivity of the peptides, 
blinded samples were sent to Dr. Michael Zigmond at the 
University of Pittsburgh for testing in cultures of newborn 
rat midbrain dopamine neurons. Peptide mixture samples Three peptides, designated GER9263, GER9264, and 
GDR9265 (see Table 1, below) were synthesized by Keck 
Biotechnology Resource Laboratory, Yale University New 
Haven, Conn. Synthetic peptides can be made routinely up 
20 (GER9263, GER9264, and GDR9265 combined in a 1:1:1 
ratio) were compared to citrate buffer alone, two different 
lots of GDNF, and Neurturin (FIG. 6). Both lots of GDNF 
and the 100 ng/ml ADNS peptide mixture exerted about the 
same effects in dopamine neuron survival, increasing sur-
to 40 residues and often, depending on sequence, up to 70 
residues by this facility. All peptides were separated and 
purified on a preparative C-18 or C-4 RP-HPLC system and 
delivered as a lyophilized material. Yields for normal pep-
tides under 40 residues were "guaranteed" at 50 mg or more 
and at 90+% purity. Yields and purity are often higher, 
varying with the peptide sequence and length. All peptides 
made in the Keck facility at the 0.5 mmole scale are done by 30 
tBOC chemistry and at a single scale range (which generates 
a theoretical crude yield of 500-1,000 mg for a 10-20 mer 
respectively). The purified peptides were characterized by 
analytical RP-HPLC, amino acid analysis, and FAB mass 
spectroscopy. 
TABLE 1 
ADNS peptides 
Peptide Sequence 
GER9263 ERNRQAAAANPENSRGK-amide (SEQ ID NO, 2) 
GER9264 FPLPA-amide (SEQ ID NO, 3) 
GDR9265 PPEAPAEDRSL-amide (SEQ ID NO, 4) 
Example 3 
Dopaminergic Activity of ADNS Peptides in 
Fischer 344 Rats 
25 viva! by about 25-30% over vehicle levels. The peptide 
mixture at a concentration of 50 ng/ml promoted an increase 
in survival of around 10%, approximately the same effect as 
100 ng/ml Neurturin, a trophic factor that is closely related 
35 
to GDNF. 
Example 5 
ADNS Peptides and Response to CNS Delivery in 
an Aged Rhesus Monkey 
A study was performed demonstrating that a mixture of 
three ADNS peptides (GER9263, GER9264, and GDR9265 
combined in a 1: 1: 1 ratio) exerts pharmacological effects on 
CNS nigral dopamine neurons in an aged rhesus monkey 
40 similar to those produced by GDNF. Marked increases of 
68-125% in stimulus-evoked dopamine release were mea-
sured in the putamen by in vivo microdialysis. Motor speed, 
as measured in fine motor hand movements, increased by up 
to 58%, into the range of young adult monkeys. General 
45 body movements increase by 38%, indicating much higher 
activity levels. The effects from unilateral treatment were 
long-lasting (for at least one month) and bilateral, similar to 
those resulting from GDNF treatment. Histopathological 
analysis of the injection sites in the substantia nigra revealed 
50 only mild, circumscribed pathology from the peptide injec-
tions. The pharmacological effects of ADNS peptides on 
upregulating nigrostriatal dopamine system functions are 
extraordinary and suggest their potential therapeutic use for Experiments were performed to test the effects of the three 
ADNS peptides (GER9263, GER9264, and GDR9265) on 
dopaminergic activity in normal young adult male Fischer 55 
344 rats. The peptides were combined in a 1: 1: 1 ratio. There 
were three test groups with six animals per group: vehicle 
(citrate buffer), vehicle plus 30 µg peptide mixture, and 
vehicle plus 100 µg peptide mixture. The vehicle or vehicle 
plus peptide solutions were steriotaxically injected in equal 60 
portions into two sites each in the right substantia nigra. 
the treatment of Parkinson's disease and age-associated 
movement dysfunctions. 
The ADNS peptides tested in this Example are three 
amidated peptides predicted to exert potent biological effects 
similar to those of Glial Cell Line-Derived Neurotrophic 
Factor (GDNF). The effects of GDNF on CNS dopamine 
neurons fall generally into three categories: pharmacological 
upregulation of dopaminergic activity, neuronal regenera-
One month after drug administration, the basal levels of 
dopamine and dopamine metabolites were measured by 
microdialysis in the right striatum. Potassium and amphet-
amine evoked release of dopamine were also evaluated. 
While basal levels of dopamine were not significantly 
altered in the striatum, average K+ -evoked release of dop-
tion and neuroprotection. This study was designed to assess 
the pharmacological effects of ADNS peptides on substantia 
nigra dopamine neurons in the nonhuman primate brain. It 
65 was previously shown that CNS delivery ofGDNF increases 
stimulus-evoked dopamine release in aged rhesus monkeys 
(Grondin et al., 2003). In addition, behavioral correlates of 
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increased dopaminergic activity were recorded in these 
animals, improved motor functions and increased motor 
speed. The present study was a case report on one aged 
monkey that received a 100 µg injection of ADNS peptides 
into the substantia nigra of the brain and was followed for 30 
days. Motor speed was measured weekly using an auto-
mated movement analysis panel (MAP) and EthoVision, a 
video tracking program. Movement features were rated 
weekly using a nonhuman primate clinical rating scale 
(Zhang, Z. et al., "Motor slowing and parkinsonian signs in 10 
aging rhesus monkeys mirror human aging. ", J Gerontol-
ogy: Biol. Sci. SSA: 0473-8480, (2000)). Stimulus-evoked 
dopamine release was analyzed by microdialysis at the 30 
day time point. The animal was then euthanized and the 
15 
brain recovered for histopathological analysis. 
Methods Used for Studying ADNS Peptides 
Animal: 
16 
surements were determined from the surface of the brain to 
the target at the lateral coordinate. 
Surgery: 
Following sedation with ketamine hydrochloride (-20 
mg/kg; i.m.) plus atropine sulfate (-0.04 mg/kg; i.m.), the 
animal was intubated via the orotracheal method and intra-
venous lines secured. Then, the animal was anesthetized 
with isoflurane (1-3%) and placed in an MRI compatible 
Kopf stereotaxic apparatus in a ventral-lateral position as per 
the coordinates previously (see Anatomical MRI above). 
The animal was maintained on a heated blanket and had 
cardiac and respiratory parameters monitored during the 
procedure, which was carried out using sterile field condi-
tions. Coordinates for peptide injections were determined by 
MRI prior to the surgery as described above. After being 
shaved, the scalp area was cleaned using antiseptic proce-
dures with sterile 4x4 sponges soaked in Betadine® surgical 
scrub followed by 70% isopropyl alcohol. This procedure 
was repeated. After the alcohol dried, Betadine® prep was 
20 applied and the animal was covered with sterile drapes. 
A thirty-four year old female rhesus monkey (ID# NJOS) 
weighing 7 kg was used. The animal was diagnosed as 
having an inoperable mammary tumor, with the attending 
veterinarian suggesting that the monkey be placed in a 
terminal study and euthanized for humanitarian reasons. The 
animal was maintained on a 12-hour light/12-hour dark 
cycle and housed individually in a cage measuring 9 square 
feet, with an elevated perch, front access doors and side rear 
access doors connecting the housing cage to an adjacent 
activity module. The diet consisted of certified primate 
biscuits given in the morning (7:30 AM), and supplemented 
daily in the afternoon (1 :30 PM) with fresh fruit or veg- 30 
etables. Water was available ad libitum. 
All procedures were conducted in the Laboratory Animal 
Facilities of the University of Kentucky, which are fully 
accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care. Veterinarians skilled in 
the health care and maintenance of nonhuman primates 
supervised all animal care. 
MRI Imaging: 
Magnetic resonance images (MRI) were obtained on a 
10.S T clinical imager (Siemens Magnetom Vision) using a 
standard cross polarized extremity coil. After being sedated 
with ketamine hydrochloride (-20 mg/kg; i.m.) plus atropine 
sulfate (-0.04 mg/kg; i.m.), the animal was anesthetized 
with sodium pentobarbital (-10 mg/kg; i.v.) and imaged to 
provide stereotaxic coordinates for peptide delivery. The 
animal's head was positioned in the extremity coil using an 
MRI compatible stereotaxic head frame. This frame kept the 
animal's head level and immobilized at the center of the 
radio frequency coil using ear and mouth bars. An initial set 
of coordinates was taken using the earbars, toothbar and a 
zeroing bar targeted to the gum line between the two upper 
middle incisors to allow replication any time the animal was 
replaced in the stereotaxic apparatus. 
The coil/frame assembly was then positioned to place the 
animal's head at magnet isocenter. Sets of Tl-weighted 
3D-FLASH images were collected for determination of the 
brain coordinates (TR/TE=22/9 ms; FA=3S 0 ; FOV=96x96x 
Then, an incision was made through the scalp and the skin 
and muscles overlying the skull were reflected. Small holes 
were drilled in the skull directly over the target area. The 
overlying meninges were removed to expose the surface of 
25 the brain. 
A 1.0 mg/ml concentration of the three-peptide mixture in 
citrate buffer was used. It was sterilized by filtration prior to 
injection Using MRI-guided procedures, a 27 G needle 
coupled to a Hamilton syringe containing 100 µI (i.e. 100 µg) 
of the peptide mixture was lowered in the right rostral SNc 
(AP: 11, L: S, DV: 30 from surface of the brain). A volume 
of SO µI was delivered using a nanopump at a rate of 1 
µI/min. This was followed by a 20 min waiting period before 
retracting the needle out of the brain (1 mm/min). The 
35 needle/syringe assembly was then moved 1 mm caudally 
and O.S mm laterally and lowered into the more caudal SNc 
(AP: 10, L: S.S, DV: 29 from surface of the brain). This was 
followed by a 20 min waiting period before retracting the 
needle out of the brain (1 mm/min). After completion of the 
40 injections, the scalp incision was sutured over the exposed 
areas per normal procedures and the animal was given an 
analgesic (buprenorphine, 0.01 mg/kg, i.m.). Vital signs 
were monitored until the animal awakened, at which point 
the animal was covered with warm blankets and taken back 
45 to its cage and monitored until it was ambulatory. 
Behavioral Tests: 
To assess changes in motor functions, the animal was 
videotaped prior to injecting the peptide mixture, and 
weekly after the injection for four weeks. The videotaping 
50 cage measured 28 in Wx32 in Hx32 in D, had a white 
background wall and a clear Lexan window permitting 
videotaping. The videotaping cage was illuminated by two 
48 in-long fluorescent lights located 30 in above. Water (via 
a cage attached bottle) was available ad libitum throughout 
55 the session. The animal was fed fruit or vegetables after 
completion of data acquisition and upon return to its home 
cage. 
90 mm; Matrix=l28xl28x90; Nacq=2; TA=6 min 48 sec). 
All images were acquired as coronal slices relative to the 
brain. Antero-posterior, lateral and vertical coordinates for 60 
stereotaxic surgery were derived from the Tl-weighted 
coronal brain images. The interaural line was identified on 
the scans by modified earbars containing Vitamin E. This 
provided a precise reference-point, which allowed for 
anteroposterior measurements to the target. Lateral measure- 65 
ments were determined by measuring the distance from the 
sagittal sinus/third ventricle to the target site. Vertical mea-
Beginning at 1 PM, a technician entered the room and 
placed small food items (e.g. g=y bears) on the ledge of 
the cage to elicit the animal to stand-up and reach out for the 
food. Then, the animal was videotaped for 30 minutes with 
no one in the room. Following this 30-minute videotaping 
period, the technician re-entered the room, stopped record-
ing and attached a non-wired version of the monkey Move-
ment Analysis Panel (MAP, see below) to the doorway of the 
cage for a hand retrieval test. Five to six preferred small food 
items (e.g. miniature marshmallows) were placed on each 
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side of the panel. The animals was given 10 minutes (default 
time) to retrieve the food items, at which point the tester 
re-entered the room and stopped recording. This portion of 
the session was videotaped, with a focus on the hands. 
Starting at 2 PM, the same procedures described above were 
repeated. At the end of the testing session, the animal was 
returned to its home cage. 
18 
A day's testing session consisted of twelve trials, six on each 
side alternating between the right and left hand. 
Microdialysis Studies: 
As described above, standardized videotaping procedures 
were conducted pre- and post-treatment. Behavioral param-
eters associated with motor function were scored from coded 
videotapes from 0 (normal) to 3 (severe disability) in the 
following categories: rigidity, bradykinesia, posture, bal-
ance, tremor, and hand dexterity (see Zhang et al., 2000). 
Rigidity is defined as a decrease in limb extension and/or 
use. Motor dysfunctions were rated in half-point increments 
by an experienced rater. 
The animal underwent bilateral putamenal microdialysis 
one month post ADNS peptide injection. Using the method 
described below, in vivo microdialysis procedures had also 
been conducted previously in the right striatum of the same 
animal (date: Feb. 10, 2004; coordinates: AP: 20.5 mm, L: 
10.2 mm, DV from cortex: 21 mm). 
1° Following normal MRI-guided stereotactic procedures 
(see Surgical procedures for ADNS peptide injection), cus-
tom-made CMA/11 dialysis probes with a membrane length 
of 3 mm and diameter of 0.24 mm (CMA Microdialysis, 
Distance traveled (cm) was quantified from 8-mm video-
tapes (SONY P6-120 MPL) using a commercially available 
video tracking system EthoVision Pro (version 2.3, Noldus 
Information Technology, Asheville, N.C.) coupled to a 
SONY Digital 8 video cassette recorder. This system runs on 
a Pentium based computer with a frame grabber card (PI-
COLO, Belgium), so that the analog video signal coming 
from the video cassette recorder is digitized and transferred 
to the computer. A window on the computer screen directly 
displays the video image, and the boundaries within which 
tracking took place were defined by accurately tracing the 
outline of the cage in the video image, in addition, two zones 
were outlined, so that the overall activity measured in the 
entire cage could be analyzed in terms of vertical (top half) 
or horizontal (bottom half) activity. As described above, the 
animal was videotaped for 60-minute periods, pre- and 
post-treatment, and the video tracks were analyzed at a rate 
15 
North Chelmsford, Mass.) were positioned (1 mm/min) 
bilaterally in the putamen (AP: 20 mm, L: 10.5 mm, DV 
from cortex: 20 mm). Probes were perfused continuously at 
a rate of 1.2 µI/min with artificial cerebrospinal fluid using 
a computerized multisyringe pump (World Precision Instru-
20 ments). Microdialysate fractions were collected at 30 min 
intervals. 
Following a I-hour application of artificial cerebrospinal 
fluid to collect baseline fractions, excess potassium (100 
mM KC!, 47.7 mMNaCI) was then included in the perfusate 
25 for a single 30-min fraction (t0-t30). Two hours later 250 µM 
amphetamine was included in the perfusate for a single 
30-min fraction (tl-t150). Three additional fractions were 
collected after discontinuing amphetamine administration 
(t180-t240). The incision was then closed as per normal 
30 surgical procedures. Microdialysate fractions were analyzed 
using standard high performance liquid chromatography 
procedures coupled with electrochemical detection. 
of 6-sample/sec. For every sample, the cage was scanned 
and the position of the tracked animal was determined by 35 
using a gray scale detection method (brightness). This 
entails calibrating the software to distinguish the dark-
colored animal from the background, which is then defined 
as all other pixels. The back wall of the cage was painted 
white to provide a background with a maximum degree of 40 
contrast with the dark-colored primate. This automated 
method relies on determining the position of the center of 
mass of the animal in the cage, and the resultant x-y 
coordinates extracted as a function of time are used for 
calculating the movement pattern during the observation 45 
period. These coordinates were subsequently related to 
actual spatial measures by calibrating the software to the 
dimension (width) of the cage, the distance traveled by the 
animal were calculated in centimeters instead of pixels. 
Tissue Collection Procedures: 
Tissue biopsies were collected for possible future use. At 
the end of the dialysis session, the animal was immediately 
euthanized. The deeply anesthetized animal (2 ml pentobar-
bital, i.v.) was transcardially perfused with heparinized 
ice-cold saline (6 L). Then, the brain was removed quickly, 
and dropped into a container of cold saline, which was 
placed on wet ice and taken back to the laboratory. Using an 
ice-cold mold, the brain was sectioned into 4-mm coronal 
slabs, rostral of the midbrain. 
Multiple tissue punches were taken bilaterally from fro-
zen 4-mm thick coronal tissue sections using a 14 G biopsy 
needle in the caudate nucleus (n=18 per side, tissue slabs #3, 
#4 and #5), putamen (n=18 per side, tissue slabs #4, #5, #6), 
nucleus accumbens (n=7 per side, tissue slabs #3 and #4) 
and globus pallidus (n=5 per side, tissue slabs #6). Separate 
needles were used for the right and left (green tape) hemi-
Movement Analysis Panel (MAP): 50 sphere. All punches were rapidly transferred to pre-weighed 
storage tubes, weighed once more, and stored at -80° C. 
Pictures of the punched slabs were taken to document the 
punching pattern, and then they were stored at -80° C. 
In addition, fine/hand motor movement times in retrieving 
food items from a platform level placed in a receptacle 
chamber were measured using an automated clear Lexan 
MAP attached to the door opening of the home cage (see 
Gash, D. M. et al. "An automated movement analysis panel 55 
for upper limb motor functions in rhesus monkeys and 
humans", J. Neurosci Methods 89:111-117, (1999) and 
Zhang et al., 2000). The receptacle chamber is divided into 
left and right halves, and is accessible on each side through 
two portals (armhole portal and receptacle portal). Move- 60 
ment times were measured by arrays of three photodiodes 
around each portal that automatically relayed to the com-
puter when one or more beams were broken by passage of 
the monkey's arm/hand. Testing was conducted in the after-
noon, prior to injecting the peptide mixture, and weekly 65 
thereafter for four weeks. Fresh fruit and vegetables were 
given to the animal after completion of the testing session. 
The midbrain was taken out as a block, which included 
the cerebellum, and post-fixed for quantitative immunocy-
tochemistry of substantia nigra dopamine neurons and TH+ 
processes. To do so, the midbrain was immediately 
immersed in 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4) at 4 ° C. for three days and transferred to 15% 
sucrose solution until saturated for sectioning. Then, a series 
of 40 µm-thick coronal sections were cut on a frozen sliding 
microtome. One out of every 12th adjacent sections was 
processed for cresyl violet (Niss!) and hemotoxylin and 
eosin (H & E) staining. Also, 1/i2th adjacent sections were 
processed for the following staining: a) 1:1000 mouse 
anti-glia fibrillary acidic protein (GFAP) antibody for astro-
cytes, b) 1:200 mouse anti-HLA-DR antibody for reactive 
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microglia, and c) 1:1000 mouse anti-tyrosine hydroxylase 
(TH) antibody for dopaminergic neurons (see Ai et al., 
2003). 
Effects of ADNS Peptides on an Aged Rhesus Money 
The animal recovered without problems from peptide 5 
delivery into the right substantia nigra. No clinically observ-
able abnormal behaviors (e.g. auto-mutilation, stereotypic 
movements, dyskinesia, vomiting) were noted throughout 
the 30-day study. 
As described above, standardized videotaping procedures 10 
were conducted pre- and post-treatment to assess changes in 
motor functions from coded videotapes. Prior to injecting 
the three-peptide mixture into the right substantia nigra, the 
animal was given a cumulative score of 3.25 points on the 
rating scale (See Table 2). Although the effect was variable, 15 
this score improved (the lower the score, the better the 
movement functions) by over 30% (i.e. 1 point) by the fourth 
week of the study. Similarly, distance traveled (cm) mea-
sured over weekly 60-minute periods using the automated 
video-tracking system (EthoVision) improved up to 38% by 20 
the fourth week post treatment versus baseline locomotor 
activity (from 7064 cm to 9780 cm). Last but not least, MAP 
performance times for left hand motor were 56% faster by 
week four post peptide treatment (from 0.81 sec to 0.36 sec). 
Right hand performance times were already faster than the 25 
left pre-peptide treatment. They further improved in the 4 
weeks post-treatment, with performance times 14% faster 
(from 0.36 sec to 0.31 sec). 
In vivo microdialysis was used to investigate the dynam-
ics of dopamine release in the basal ganglia. Measurements 30 
were carried out in the right putamen four weeks post 
peptide treatment (see FIGS. 7A and B). In particular, FIG. 
7 shows the results of potassium (K+) and d-amphetamine 
(d-AMPH) evoked release of dopamine measured in the 
right putamen of NJ05 using microdialysis to collect 35 
samples for neurochemical analysis. FIG. 7A shows the first 
recordings made Feb. 10, 2004, several years prior to the 
ADNS peptide study. In aging monkeys, dopamine evoked 
release of dopamine to K+ and d-AMPH normally decreases 
with increasing age. FIG. 7B shows the second set of 40 
recordings made thirty days after ADNS peptide injections 
into the right substantia nigra on Apr. 27, 2006. K + evoked 
release was increased from the 2004 reading from 36.5 nM 
to 82 nM. D-AMPH evoked release of dopamine increased 
from 74 nM to 125 nM after ADNS peptide administration. 45 
Thus, in comparison to measurements recorded under simi-
lar conditions two years earlier in the same animal, potas-
sium-evoked overflow of dopamine was increased by 125% 
at 30 days postADNS peptide administration (from 36.5 nM 
to 82 nM). Similarly, amphetamine-induced overflow of 50 
dopamine was increased by 68% compared to measurements 
recorded two years earlier (from 74 nM to 125 nM). 
20 
FIGS. SA and B, this injection site (arrow) was just dorsal 
to the substantia nigra, pars compacta (SNc). While there is 
an evident response at the injection site and a smaller 
satellite area (*) of reactivity dorsal to the main area, the 
injury response is very circumscribed. FIG. SC shows that 
reactive astrocytosis, as assessed by GFAP positive reactiv-
ity around the needle track, is minimal, approximately that 
expected from a needle tract injury alone. In FIGS. SD and 
E, the injury response appears similar using H & E to that 
seen with Niss!. The injury response is localized and does 
not seem to involve adjacent cells. Reactive microglia 
(HLA-DR+cells) are a prominent constituent of the injury 
response (arrow and *, FIG. SF). (In FIG. S, Cerebral 
peduncle=CP; Substantia nigra reticulatia=SNr; Ventral 
Tegmental Area=VTA. Scale bars are included in each 
photomicrograph.) The injection site showed reactive cells 
in an area about 200 µm wide by 400 µm long in Nissl-
stained and H & E-stained sections (FIGS. SA, B, D and E). 
The response consisted of activated microglia (HLA-DR 
positive cells, FIG. SF). The absence of pronounced GFAP 
immunostaining (FIG. S) indicated that the injection did not 
stimulate a glial reaction. 
The substantia nigra pars compacta (SNc) containing the 
population of dopamine neurons that degenerates in Parkin-
son's disease is evaluated in the series of photomicrographs 
set forth in FIG. 9. In FIG. 9A, Nissl-rich neurons (arrow-
heads) adjacent to the peptide injection site (*) appear 
normal with prominent nuclei evident in the nucleus of some 
cells. Niss! staining corresponds to the presence of rough 
endoplasmic reticulum in the cytoplasm and indicates cells 
actively synthesizing protein. The H & E stained section in 
FIG. 9B also shows neurons with normal features (arrow-
heads) adjacent to the injection site(*). FIG. 9C shows that 
there are only a few scattered activated microglia (arrow-
heads showing HLA-DR positive cells) in the SNc. Large 
numbers would indicate ongoing pathological processes. 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in 
dopamine synthesis. The TH positive cells shown in FIG. 9D 
are dopamine neurons. Their size and exuberant expression 
of TH positive processes are indicative of healthy, active 
cells. Scale bars are included in each photomicrograph. 
Dopamine neurons in the substantia nigra appeared to be 
normal (FIG. 9). Tyrosine hydroxylase immunostaining 
(FIG. 9D) revealed large dopamine neuron perikarya (cell 
bodies) with extensive neuritic processes. Along with the 
Niss! and H & E stained sections (FIGS. 9 A and B), the 
nigral cells showed features characteristic of healthy neu-
rons. A few activated microglia (HLA-DR positive cells, 
FIG. 9C) were present in the nigral region, a typical feature 
of this brain region in healthy aged monkeys. Large numbers 
of activated microglia would be indicative of an ongoing 
disease process. 
The subject in this study was a very old rhesus monkey, 
34 years old. One year for a rhesus monkey is roughly 
Basal levels of dopamine and dopamine metabolites in the 
striatum were determined from measurements in the 
microdialysates prior to potassium and amphetamine stimu-
lation. Basal dialysate levels of dopamine and HVA showed 
small changes from the baseline levels two years earlier 
(Table 2). However, basal levels of extracellular DOPAC 
were increased by 230% at thirty days post peptide injection 
compared to the earlier baseline measures (Table 3). 
55 equivalent to three years of human life, making this animal 
equivalent to a 100 year old person. The monkey was used 
in this study because it had a terminal disease, mannnary 
cancer. The closest comparable monkeys in an earlier study 
treated with GDNF were 22-24 years old (Grondin et al., 
The histopathological response to the injection of peptides 
in the nigral region was mild (see FIGS. Sand 9). In FIG. 
S, one of the injection sites (arrow) is shown using standard 
histochemical techniques for Niss! staining and hematoxylin 
and eosin (H & E) staining Immunostaining was conducted 
to assess the response of astrocytes (GFAP positive cells) 
and microglia (HLA-DR positive cells) to the injections. In 
60 2003). They received infusions of GDNF into the brain for 
24 weeks while NJ05 had a single injection of an ADNS 
peptide mixture and was monitored for one month. Despite 
the differences, many of the responses were comparable to 
those seen to GDNF. NJ05 motor performance times on the 
65 MAP improved within four weeks on both the right (14%) 
and left (56%) sides. The improved motor speeds 
approached the speeds of aged monkeys receiving GDNF 
US 9,586,992 B2 
21 
and those of normal young adult animals. Consistent with 
increased motor speed, general locomotor activity was 
increased by 38% by four weeks of treatment in NJ05. 
There were neurochemical changes in NJOS's brain along 
with the behavioral improvements. Both potassium- and 
amphetamine-evoked release were increased (125% and 
68%, respectively) in the putamen in comparison to pre-
treatment levels. This was similar to the increased evoked 
release of dopamine in response to the same stimulants in 
aged rhesus monkeys treated with GDNF (Grondin et al., 
2003). Basal dialysate levels of dopamine, HVA and 
DOPAC showed high variability, but were not significantly 
changed in aged GDNF recipients. NJOS's basal dopamine 
and dopamine metabolite levels were in the same range as 
the GDNF and vehicle-treated old animals. The only dra-
matic change seen in this animal was in DOPAC levels, 
which increased over three-fold post ADNS peptide treat-
ment. The significance of this response is that it reflects 
higher levels of dopamine metabolism in the striatum. 
Histopathology was much less extensive than the damage 
in the same region from the infusion ofGDNF (see Gash, D. 
M. et al., "Trophic factor distribution predicts functional 
recovery in parkinsonian monkeys", Ann Neurol 58(2):224-
33 (2005)). The dopamine neurons in the substantia nigra 
appeared healthy, with numerous neuritic processes. 
TABLE 2 
Changes in motor functions post ADNS peptides delivery into the right 
substantia nigra. The reduction in the disability score means that the 
motor fllilctions such as walking and balance were improving. 
The locomotor activity level increases by week four also reflect 
that the animal was increasing the time and distance in walking. 
The Movement Analysis Panel (MAP) scores demonstrate much 
faster hand fine motor movements by week 4 after treatment. 
Disability 
Score (pts )/% 
Treatment baseline 
Baseline 3.25 
Week 1 2.00/-38% 
Week2 2.00/-38% 
Week3 2.50/-23% 
Week4 2.25/-31 % 
Locomotor 
Activity 
(cm)/% 
baseline 
7064 
8422/+19% 
7136/+1% 
6368/-10% 
9780/+38% 
TABLE 3 
Left Map 
Times (sec)/% 
baseline 
0.81 
0.86/+6% 
1.09/+35% 
0.75/-7% 
0.36/-56% 
Right MAP 
times (sec)/ 
% baseline 
0.36 
0.45/+25% 
0.39/+8% 
0.34/-6% 
0.31/-14% 
Changes in basal dialysate levels of dopamine and dopamine metabolites 
in the right putamen, 30 days post ADNS peptide delivery into the right 
substantia nigra. The large increase in levels of the dopamine metabolite 
DOPAC indicate increase doparninergic activity. As the enzyme 
(monoamine oxidase B) for metabolizing dopamine to DOPAC is on the 
outer membrane of mitochondria, it also reflects either more active 
mitochondria and increased nwnbers of mitochondria. 
Hemisphere 
Pre-peptides 
Post-peptides 
Dopamine (nM) 
5.6 
4.9 
HVA(nM) 
5033 
4191 
Example 6 
Materials and Methods 
DOPAC (nM) 
127 
419 
The following materials and methods were used in the 
following examples. 
Materials: 
Unless otherwise stated, all cell reagents and assays were 
purchased from Invitrogen. All other materials and chemi-
cals are reagent grade. 
22 
DNSP-17 (GER 9263), DNSP-5 (GER 9264), DNSP-11 
(GER 9265), and Biotinylated DNSP-11: DNSP-17 (se-
quence: ERNRQAAAANPENSRGK-amide (SEQ ID NO: 
2)), DNSP-5 (sequence: FPLPA-amide (SEQ ID NO: 3)): 
DNSP-11 (sequence: PPEAPAEDRSL-amide (SEQ ID NO: 
4)) and biotinylated DNSP-11 (bDNSP-11; sequence: bio-
tin-PPEAPAEDRSL-amide (SEQ ID NO: 4)) were synthe-
sized and RP-HPLC purified to >98% by AC Scientific 
(Duluth, Ga.) and the W. M. Keck Foundation Biotechnol-
10 ogy Resource Laboratory at Yale University. Peptides were 
characterized for purity and correct sequence by MALDI-
TOF LC-MS and Edman degradation. DNSP-11 was deter-
mined to be stable, in vitro, at a variety of experimentally 
relevant concentrations and temperatures, including 37° C. 
15 in sterile pH 5 citrate buffer for 31 days. 
Tissue Preparation for DNSP-11 Staining in Substantia 
Nigra at Postnatal Day (PNlO): 
Tissue was prepared from SD pups. Brains were rinsed in 
Dulbecco's Phosphate Buffered Saline (DPBS, Gibco), and 
20 submerged in 4% paraformaldehyde pH 7.4 for 48 hours. 
Following submersion in 30% sucrose, brains were sec-
tioned coronally (40 µm) and stored in cryoprotectant solu-
tion at - 70° C. until processed for immunohistochemistry. 
DNSP-11 Treatment of Mesencephalic Cells: 
25 Timed pregnant SD rats (Harlan) were used to obtain the 
ventral mesencephalon from E14 fetuses. The dissected 
tissue was collected in cold Neurobasal™ medium and 
rinsed twice with cold Dulbecco's PBS. The cells were 
chemically (TrypLE®) and mechanically dissociated to 
30 yield a single cell suspension. The solution was centrifuged 
at 169 g for 6 minutes and the pellet was resuspended in 
Dulbecco's Modified Eagle Medium (DMEM). Cells were 
plated in a 25 µL micro-island at a density of 4000 cells/µL 
on poly-D-lysine coated 24-well plates (Sigma). Following 
35 adherence, cells were supplemented with warm Neu-
40 
robasal™ media containing 2 mM glutamine, lxN2 , and 100 
units of penicillin/streptomycin. Neurotrophic compounds 
were added at each media addition, including initial plating 
and DIV 2. A dose response of the peptides (0.03 ng to 10 
ng/mL) was added to a 24-well plate following media 
supplementation. 
MN9D Cell Cultures: 
The MN9D cell line has been described by Choi (1991) 
Brain Res. 552:67-76 and was a gift from Michael Zigmond. 
45 Cells were cultured in DMEM supplemented with 10% Fetal 
Bovine Serum (FBS, Hyclone), 50 U/mL penicillin and 
streptomycin. For experiments, the cells were plated on 
24-well poly-D-lysine in DMEM with 1% (v/v) penicillin-
streptomycin. The cells were grown at 37° C. in 5% C02 . 
50 Caspase-3 Activity Assay in MN9D Cells: 
MN9D cells were plated to 100,000 cells/well. Cell 
cultures were exposed to DNSP-11 (1 ng/mL) or buffer for 
1 hour prior to 15 min 100 µM 6-0HDA exposure. Cas-
pase-3 activity was monitored after 3 hours by fluorescence 
55 (excitation/emission 496/520 nm) using the Enz Chek Cas-
pase-3 kit. Protein levels of lysed cells were measured by 
BCA assay (BioRad) and normalized for every experiment. 
Data expressed as % control and repeated a minimum of 3 
times. 
60 Terminal dUTP Nick-End Labeling (TUNEL) Assay in 
MN9D Cells: 
After treatment with DNSP-11, MN9D cells were fixed 
and labelled to assess degenerative nuclear changes as 
indicated by the extent of high-molecular weight DNA 
65 strand breaks. DNA fragmentation was detected by using 
steptavidin-horseradish peroxidise conjugate followed by 
the substrate diaminobenzidine (DAB) generating a colored 
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precipitate. Ratios between apoptotic and total cells were 
determined ( 4 random fields/well; 4 wells/group). Experi-
ments were repeated 3 times. 
Double Fluorescent Immunostaining of DNSP-11: 
24 
Floating sections were pretreated with 0.2% H20 2 in 5 
potassium phosphate buffered saline (KPBS) for 10 minutes 
and blocked with 4% normal goat serum in KPBS for 1 hour. 
Then, sections were incubated overnight with both rabbit 
anti-hDNSP-11 antibody (1:2000, Alpha Diagnostic) and 
mouse anti-TH antibody (1:1000, Chemicon) in KPBS at 4° 10 
C. After washing with KPBS, the sections were incubated 
with Alexa-488 conjugated goat anti-rabbit IgG (1:500, 
Molecular Probes) and Alexa-568 conjugated goat anti-
mouse IgG (1:500, Molecular Probes) for 3 hours. The 
sections were washed extensively and visualized with a 15 
Nikon fluorescence microscope. 
19: 1202-4 with 20 mM HEPES, pH 7.4) and cytosolic 
fraction (supernatant) collected after 30 minutes at 100,000 
g. 50 µg of bDNSP-11 was incubated with fraction for 15 
minutes on ice. Sample was added to streptavidin magnetic 
beads (New England Biolabs), pelleted, and washed four 
times in homogenization buffer. Bound proteins were eluted 
by Solubilization/Rehydration Solution (7M Urea, 2M Thio-
urea, 50 mM DTT, 4% CHAPS, 1 % NP-40, 0.2% Carrier 
ampholytes, 0.0002% Bromophenol blue), and analyzed by 
2D-PAGE and MALDI-TOF MS. 
Example 7 
Neurobiological Actions of DNSP-11 
GDNF is endogenously produced as a pre-proprotein of 
211 amino acids that is processed and secreted as a mature 
homodimer with a molecular weight of 32-42 kDa. The 
following examples illustrate the neurobiological actions of 
Animals and Surgical Procedures for Normal and 
6-0HDA-Lesioned Rats: 
Fischer 344 (F344) rats were used for all experiments and 
maintained under a 12 hour light/dark cycle with food and 
water provided ad libitum. All procedures were approved by 
the University of Kentucky Institutional Animal Care and 
Use Committee following AAALACI guidelines. 
Infusion Delivery of DNSP-11 or Vehicle: 
Isoflurane anesthetized (1.5-2.5%) F344 rats received 5 µl 
of 6 µg/µL DNSP-11 solution or citrate buffer vehicle 
solution in a blinded manner. Treatment was delivered to the 
nigral cell bodies using the same stereotaxic coordinates and 
protocol for solution delivery as in studies of GDNF13 . 
Reverse Microdialysis: 
Reverse in vivo microdialysis was accomplished using 
methods and brain coordinates described by Hebert et al. 
(1996) J. Pharmacol. Exper. Ther. 279:1181-1190. CMA 11 
microdialysis probes with a 4.0 mm membrane length and 6 
kDa molecular weight cut-off were placed within the rat 
stria tum. 
Unilateral 6-0HDA Lesions: 
The 6-0HDA solution was delivered to two injection sites 
along the medial forebrain bundle (MFB) using a protocol 
described by Lundblad et al. (2002) Eur. J. Neurosci. 
15:120-132. Five weeks after the unilateral 6-0HDA MFB 
lesion procedure, animals were grouped based on apomor-
phine (0.05 mg/kg, s.c.)-induced rotational behaviour: Ani-
mals with >300 rotations per 60 minutes were selected. 
Lesioned animals received 5 µL of either a 20 µg/µL 
DNSP-11 solution or citrate buffer vehicle solution in a 
manner similar to infusion delivery in normal animals. 
Neurochemical Content of Tissue: 
Lesioned animals were euthanized 5 weeks after DNSP-
20 dopamine neuron stimulating peptide-11 (DNSP-11 ), an 
11-mer peptide that has been independently predicted to be 
an endopeptidase cleavage product from the human GDNF 
prosequence (FIG. lOA). 
FIGS. lOA and lOB illustrate the sequence origin and 
25 homology of DNSP-11. DNSP-11 (filled) is an 11 amino 
acid sequence present in the proprotein region of the 211 
amino acid human preproGDNF sequence. After cleavage of 
the pre-signal sequence (shaded), DNSP-11 is predicted to 
be cleaved from the proprotein at flanking dibasic cleavage 
30 sites by endopeptidases. Further predicted processing yields 
the C-terminal amidated peptide. The N-terminal (striped) 
and C-terminal (checkered) proprotein fragments and 
mature GDNF (open) protein are shown. The sequence 
figure is not drawn to scale to highlight the processing of 
35 DNSP-11. DNSP-11 (FIG. lOB) shows high sequence 
homology to the rat and mouse proGDNF sequences sug-
gesting a conserved function. 
In vivo expression of the DNSP-11 sequence in the 
substantia nigra of the ventral mesencephalon from SD pups 
40 at postnatal day 10 (PNlO) was examined. Immunostaining 
for DNSP-11 in the mesencephalon of the SD pups indicated 
that the sequence is present endogenously in tyrosine 
hydroxylase positive (TH+) dopaminergic neurons of the 
substantia nigra at PNlO ns (yellow). The DNSP-11 
45 sequence colocalized within dopaminergic cell bodies at 
PNlO. 
The neurotrophic effects of DNSP-11 were studied by 
11 or vehicle infusion. The brains were sliced into 1 mm 50 
comparing its effects to the well-known effects ofGDNF on 
the maintenance of primary mesencephalic cell cultures 
from E14 SD rat embryos. E14 SD rat embryo primary 
dopaminergic neurons from the ventral mesencephalon were thick sections. Tissue punches were taken from the striatum 
and the substantia nigra and they were weighed, quick 
frozen and stored at - 70° C. until they were assayed by high 
performance liquid chromatography with electrochemical 
detection as described by Hall et al. (1989) LC/GC-Mag Sep 
Sci 7:258-265. 
Apomorphine-Induced Rotational Behavior Testing: 
Lesion severity was assessed prior to DNSP-11 treatment 
using apomorphine (0.05 mg/kg, s.c.)-induced rotational 
behavior. Beginning one week after DNSP-11 treatment, 
apomorphine-induced rotational behavior was monitored 
weekly for four weeks as described by Hoffer et al. (1994) 
Neurosci Lett. 182:107-111 (1994) and Hudson et al. (1993) 
Brain Res. 626:167-174 (1993). 
DNSP-11 Pull-Down Analysis: 
The F344 substantia nigra was homogenized in homog-
enization buffer (modified from York et al. (2005) FASED J. 
grown for 5 days in vitro and neurotrophic molecules were 
added at each media change, including initial plating and 
day 2. GDNF (FIG. llA, open bars) and DNSP-11 (FIG. 
55 llA, solid bars) were added at various concentrations (0.03, 
0.1, 1.0 and 10 ng/ml; 10 mM citrate buffer+150 mM NaCl, 
pH 5) and were seen to significantly increase TH+ neuron 
counts (+SD; one-way ANOVA with Newman-Keuls post 
hoc analysis, *p<0.05 and** p<0.01) Specifically, DNSP-11 
60 increased cell survival 75% over citrate buffer control, as 
indicated by immunocytochemical staining of TH+ neurons 
5 days in vitro (FIG. llA). Furthermore, DNSP-11 signifi-
cantly enhanced morphological changes consistent with a 
neurotrophic molecule including: neurite length, total num-
65 ber of branches, and increased total number of TH+ cells 
(Table 4; FIG. llB). These effects were similar to those 
observed for GDNF in these cells, including an increase in 
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the size of TH+ neurons, which was not observed for 
DNSP-11 (Table 4). Photographs in FIG. llB of treated E14 
primary dopaminergic neurons demonstrate that both GDNF 
and DNSP-11 treated cells (0.1 ng/ml) displayed enhanced 
cell survival, neurite length, and total number of branches. 5 
In Table 1, cell survival and morphological parameters 
were quantified for control (citrate buffer) and experimental 
(0.1 ng/ml GDNF or 0.1 ng/ml DNSP-11) conditions. For 
morphology, five fields per well (minimum of 15 cells/field; 
3-4 independent experiments) were photographed at 20x 10 
magnification and quantified using a Bioquant Image Analy-
sis System. DNSP-11 increased cell survival and morpho-
logical parameters comparable to GDNF, including com-
bined neurite length and total branches. Soma size was not 
increased by the addition of DNSP-11. A one-way ANOVA 15 
was used to test for significance among groups, followed by 
a Newman-Keuls post hoc analysis. Significance between 
control and experimental conditions was determined at 
*p<0.05 and **p<0.01. 
TABLE 4 
GDNF DNSP-11 
Control 0.1 ng/ml Control 0.1 ng/ml 
Cell survival 100 ± 15 *158 ± 12 100 ± 16 *161 ± 17 
n~8 n~8 n~7 n~7 
Combined neurite 242 ± 12 **310 ± 16 222 ± 11 **306 ± 23 
length (um) n ~ 135 n ~ 106 n ~ 139 n ~ 59 
Soma size (um2) 171 ± 4 177 ± 4 168 ± 3 165 ± 5 
n ~ 135 n ~ 106 n ~ 139 n ~ 59 
Average branches 3.8 ± 0.2 **4.7 ± 0.2 3.1 ± 0.2 **4.4 ± 0.3 
per neuron n ~ 135 n ~ 106 n ~ 139 n ~ 59 
20 
25 
30 
26 
pacta (SNc). The fluorescent immunostaining for DNSP-11, 
TH and the merger of photomicrographs from each showed 
that TH-positive dopamine neurons populate the SNc and 
the ventral tegmental area (VTA). Higher power micro-
graphs from the SNc. DNSP-11 immunostaining revealed 
uptake into the perikaryon, nucleus, and neurites of TH+ 
cells. 
At 1.5 hrs post-injection, staining for TH+ and DNSP-11 
showed overlap in the pars compacta of the substantia nigra 
and some labeling in the pars reticulata, supporting potential 
uptake of DNSP-11 into GABAergic neurons. Immunohis-
tochemical staining for DNSP-11 diminished 3 hrs after 
injection and was absent at 24 hrs and beyond, indicating 
that there is a rapid uptake of DNSP-11 into neurons. 
Example 9 
Effect of DNSP-11 on Dopamine Neurochemistry 
Prior studies with GDNF have shown robust effects on 
both potassium and amphetamine-evoked release 28 days 
after a single injection into the rat substantia nigra (Hebert 
et al. (1997) J. Pharm. Exp. Thera. 282: 760) indicating the 
functional effects of this trophic factor on dopamine signal-
ing in the normal rat striatum. In the present experiment, 30 
µg of DNSP-11 was injected into the right substantia nigra 
of normal young male Fischer 344 rats. Twenty-eight days 
after injection, in vivo microdialysis was performed in these 
animals to investigate dopamine neurochemistry in the ipsi-
lateral striatum. Resting levels of dopamine, 3,4-dihydroxy-
phenylacetic acid (DOPAC) and homovanillic acid (HVA) 
were significantly increased by over 100% in the DNSP-11 
treated rats as compared to controls (FIG. 12A). These data 
indicate longer term effects of DNSP-11 on dopamine neu-To evaluate DNSP-11 's neuroprotective properties, 
DNSP-11 was compared to GDNF in its protection against 
6-0HDA-induced toxicity in the dopaminergic cell line, 
MN9D. MN9D dopaminergic cells were incubated for 1 
hour with either citrate buffer (control), 1 ng/mL of DNSP-
35 ron function, and are analogous to prior results involving 
GDNF administration in rats and nonhuman primates. Win-
kler et al. (1996) J. Neurosci. 16: 7206; Hebert et al. (1996) 
J Pharmacol Exper Ther. 279: 1181-1190 (1996). 
The in vitro studies and in vivo measures of the effects of 
40 DNSP-11 led to an investigation of the potential neurorestor-
ative properties of DNSP-11 to damaged dopamine neurons 
in a unilateral rat model of PD. Fischer 344 rats received 
dual-site unilateral injections of 6-0HDA to produce exten-
11 orGDNF prior to 100 µM 6-0HDAexposure for 15 min. 
Data are +SD, one-way ANOVA with Tukey's post hoc 
analysis, *p<0.05, **p<0.01, ***p<0.001 vs. control; 
#p<0.05, ##p<0.01, ###p<0.001 vs. 6-0HDA. As seen in 
FIGS. llC and D, 100 µM 6-0HDA significantly increased 
TUNEL staining and caspase-3 activity in MN9D cells 
(FIGS. llC and D). Pretreatment with DNSP-11 or GDNF 45 
produced a significant reduction in the percent of TUNEL 
positive cells and caspase-3 activity (FIGS. llC and D). 
Thus both DNSP-11 and GDNF protect against 6-0HDA 
toxicity as demonstrated by reductions in TUNEL staining at 
sive destruction of the ascending dopaminergic system that 
resulted in a greater than 99% depletion of striatal dopamine 
content ipsilateral to the site of the 6-0HDA injections. Rats 
were tested 3-4 weeks after the injection of 6-0HDA using 
low-dose (0.05 mg/kg, i.p.) apomorphine-induced rotational 
behavior. In rats that rotated greater than 300 tums/60 
minutes, 30 µg of DNSP-11 was injected into the ipsilateral 
substantia nigra. DNSP-11 produced a significant -50% 
24 h (FIG. llC) and caspase-3 (FIG. llD) activity at 3 h 50 
after 6-0HDA exposure. 
Example 8 
Uptake of DNSP-11 into Neurons 
Additional studies were carried out to determine ifDNSP-
11 is actively taken up into dopamine-containing neurons in 
vivo. A single administration of 30 µg of DNSP-11 was 
delivered into the rat substantia nigra. Animals were eutha-
nized at 0.5, 1.5, 4, 24 and 48 hrs after injection to visualize 
distribution of DNSP-11 using antibodies raised against 
DNSP-11 and the ubiquitinated form of DNSP-11. DNSP-11 
antibodies labelled the cytosol and neurites of neurons in the 
area of the substantia nigra within 30 minutes after injection. 
DNSP-11 was taken up by neurons in both the substantia 
nigra, pars reticulata (SNr) and substantia nigra, pars com-
decrease in apomorphine-induced rotational behavior that 
was significant 1 week after administration and this effect 
was maintained for at least 4 weeks after DNSP-11 (FIG. 
55 12B). At 5 weeks, the substantia nigra and striatum from 
each rat was analyzed by high performance liquid chroma-
tography coupled with electrochemical detection. A single 
injection of DNSP-11 was found to significantly increase 
levels of dopamine and the dopamine metabolite, DOPAC, 
60 by -100% in the substantia nigra, indicating that DNSP-11 
has a powerful neurotrophic-like restorative effect on dop-
amine neurons in this animal model of late stage PD (FIG. 
12C). 
As shown in FIG. 12A, 28 days after DNSP-11 or citrate 
65 buffer vehicle was delivered to the nigral cell bodies, the 
DNSP-11 treatment group showed significantly higher basal 
neurochemical concentrations of DA, DOPAC and HVA. 
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Basal DA increased from 26.0±2.7 nM in the vehicle treat-
ment group to 45.8±7.7 nM in the DNSP-11 treatment group 
(tc31 )=2.255, p=0.0314). Basal concentrations of DOPAC 
increased from 3355±338 nM in the vehicle group to 
6544±836 nM in the DNSP-11 group (tc31 )=3.293, 5 
p=0.0025), and HVA, increased from 2419±251 nM with 
vehicle treatment to 4516±502 nM with DNSP-11 treatment 
(t(3o)=3.588, p=0.0012). All data were analyzed using a 
two-tailed unpaired t-test * p<0.05. FIG. 12B shows the 
results of assessment of apomorphine (0.05 mg/kg) induced 10 
rotational behavior prior to infusion treatment (Pre) and 
once weekly for 4 weeks after DNSP-11 or vehicle treat-
ment. Drug-induced rotational behavior is expressed as a 
percentage of vehicle treatment and showed a significant 
decrease in rotational behavior beginning one week after 15 
DNSP-11 treatment that lasted for all 4 weeks post DNSP-
11. The data were analyzed using a one-way ANOVA for 
repeated measures (Fc4 •39)=4.807, p=0.0005) with Bonfer-
roni's multiple comparison test * p<0.05, ** p<0.01, *** 
p<0.001. FIG. 12C shows that DNSP-11 treatment signifi- 20 
cantly increased levels of DA, (74%) and DOPAC (132%) in 
the substantia nigra of unilateral 6-0HDA-lesioned rats. DA 
content was determined to be 34.7±6.4 ng/g in the vehicle 
treatment group and 59.1±7.3 ng/g in the DNSP-11 treat-
ment group (tc13)=2.521, p=0.0265). DOPAC tissue content 25 
was determined to be 7.10±1.40 ng/g in the vehicle treat-
ment group and 16.48±4.01 ng/g (tc13)=2.33, p=0.0364) in 
the DNSP-11 treatment group. All data were analyzed using 
a two-tailed unpaired t-test, * p<0.05. 
30 
Example 10 
Interaction of DNSP-11 with Protein Partners 
In order to identify the interactions of DNSP-11 with 35 
protein partners and to gain insight into the cellular mecha-
nisms involved with the actions of DNSP-11, a pull-down 
assay was performed with homogenate from isolated sub-
stantia nigra of normal young Fischer 344 rats. Cytosolic 
and membrane fractions were collected and incubated with 40 
biotinylated DNSP-11 for 30 minutes. Bound proteins were 
pulled down by strepavidin magnetic beads, extensively 
washed to remove non-specific binders, eluted with solubi-
lization/rehydration buffer and separated by 2D-PAGE. 
Specifically, a solution of 25 µL GFRal (1 mg/mL) was 45 
incubated with 50 µL of Dynabeads® (Invitrogen) in wash 
and bind buffer (O. lM sodium phosphate, pH 8.2, 0.01 % 
Tween® 20) for 10 minutes at room temperature. The beads 
were then washed three times in 100 µL of wash and bind 
buffer. 2 µg of GDNF was added and incubated for 1 hour 50 
at 4° C. 25 µL GFRal (1 mg/mL) was incubated with 40 µg 
28 
GDNF (FIG. 13; F-Flow through, E-Elution). Moreover, the 
absence of interaction between GFRal with DNSP-11 is 
supported by ELISA. 
A gel filtration study was performed using a 120 mL 
Sephacryl S-200 column at a constant 1 mL/min flow rate. 
Individual 300 µM solutions of GAPDH (-150 kDa; FIG. 
14, dotted line) or GDNF (-30 kDa; FIG. 14, dashed line) 
eluted at expected retention times for their sizes of 50 min 
(FIG. 14, star) and 64 min (FIG. 14, pound sign), respec-
tively. When a pre-equilibrated (1 h), equimolar solution of 
GAPDH and GDNF was analyzed by gel filtration chroma-
tography, two equally intense peaks were observed (FIG. 14, 
solid line) with retention times identical to the individual 
solutions. These data demonstrate that GDNF does not 
interact with GAPDH in solution, thereby providing evi-
dence that DNSP-11 has an independent mechanism of 
action relative to mature GDNF. 
Taken together, these data indicate that DNSP-11 exhibits 
potent neurotrophic actions analogous to GDNF, but likely 
signals through pathways that do not directly involve the 
GFRal receptor. 
The foregoing examples demonstrate that DNSP-11 
shares many physiological and neurotrophic properties with 
mature GDNF, including neuroprotection and promoting 
differentiation in primary dopamine neuron cell cultures; 
increasing dopamine release and metabolism in vivo; and 
decreasing apomorphine-induced rotations and enhancing 
dopamine function in the substantia nigra of 6-0HDA 
lesioned rats. 
Example 11 
DNSP-11 Solubility and Stability 
The backbone secondary structure of DNSP-11 was 
examined using circular dichroism spectroscopy in the far-
UV region (CD; University of Kentucky Center of Structural 
Biology). The DNSP-11 spectrum (FIG. 15A) displayed a 
broad minimum mean residue ellipticity (MRE) at 200 nm, 
indicative of a peptide that it is dynamic and samples 
multiple confirmations. Small shoulders between 208-230 
nm indicate that DNSP-11 appears to be sampling polypro-
line II and other helical structures. Collectively, the spec-
trum ofDNSP-11 shows that it has characteristics of typical 
small, soluble, functional peptides of similar length. 
Reverse Phase HPLC(RP-HPLC; FIG. 15B); University 
of Kentucky Center of Structural Biology) and electro spray 
mass spectrometry (University of Kentucky Mass Spectrom-
etry Facility) were used to monitor at the stability of 
DNSP-11. DNSP-11 was stored in citrate buffer (10 mM 
Citrate+150 mM NaCl, pH 5.0) at -80° C. and 37° C. for 30 
days. These temperatures were chosen based on their rel-
evance to long term storage and use in future studies. The 
results of these studies showed that the peptides were stable 
of biotinylated DNSP-11 (bDNSP-11) for 1 hour at 4° C. 
They were then added to 50 µL of hydrophilic streptavidin 
magnetic beads (New England Bio labs) and incubated for an 
hour at 4° C. 
Several spots were observed in both the cytosolic and 
membrane fractions, indicating that DNSP-11 is able to bind 
proteins found within the substantia nigra. To identify these 
binding partners, protein bands were excised from the gels, 
trypsin digested, and analyzed by MALDI-TOF mass spec-
trometry. From these preliminary studies, approximately 20 
proteins were identified. Of these, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), a protein with a link to PD 
and apoptosis, was identified. This result was confirmed by 
in vitro pull down assays with pure GAPDH and DNSP-11. 
55 at both temperatures for one month without any appreciable 
loss of peptide (FIG. 15C). 
In addition, a pull-down assay ofDNSP-11 with GFRal 
indicated that the two molecules do not interact, like mature 
Our analysis of the effects of DNSP-11 on dopamine 
neurons in the nigrostriatal system of the brain of young 
adult F344 rats at 28 days following a single injection of the 
60 peptide, demonstrated a surprising effect, i.e., an increase in 
basal tissue levels of the dopamine metabolite 3,4-dihy-
droxyphenylacetic acid (DOPAC, see FIG. 16). The 100% 
increase in DOPAC was unprecedented in our numerous 
experiments over the past 20 years. In fact, we have never 
65 seen a dopamine-altering agent, which increases the metabo-
lism of dopamine by 100% and this effect was seen to persist 
for one month after a single injection of DNSP-11 into the 
US 9,586,992 B2 
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substantia nigra, which is the source of the dopamine-
containing fibers measured in the striatum. GDNF, which 
augmented the evoked release of dopamine by over 100%, 
30 
observed into neurons in both areas. Pyramidal neurons in 
the cortex accumulated DNSP-11. 
In summary, DNSP-11 is taken up within 30 minutes by 
increased basal levels of DO PAC by only 20-25% in young neurons in all brain areas evaluated. The uptake sites appear 
and aged rats (Herbert et al. J. Pharmacol. Exp. Therapeut. 5 to be specific for axons, dendrites, synaptic terminals and 
perikarya of nerve cells. DNSP-11 immunostaining is found 
in the cytoplasm and then in the nucleus. The half-life of 
DNSP-11 in the rat brain is under 24 hours. The areas of the 
(1996) 279:1181-1190, and Hebert and Gerhardt, J. Phar-
macol. Exp. Therapeut. (1997) 282:760-768). Based on the 
results presented herein, and the knowledge that DOPAC is 
produced when dopamine is metabolized by monoamine 
oxidase B, (an enzyme on the outer membrane ofmitochon- 10 brain studied (substantia nigra, striatum, hippocampus and 
dria (Edmondson et al, Curr. Med. Chem (2004) 11(15:1983- cortex) have major roles in cognitive and motor functions. 
93) and then the product of this reaction is metabolized by Tropic actions of DNSP-11 could protect these brain areas 
aldehyde dehydrogenase (which resides in the cytosol of from injury and/or promote restoration from disease and 
cells) we reasoned that DNSP-11 increases mitochondrial 
15 
injury processes. 
functions and thereby increases monoamine oxidase levels. 
The following examples address this. 
Example 12 
DNSP-11: Distribution, Uptake and Half-Life in the 
Brain 
20 
Example 13 
DNSP-11 Induced Changes in Genes Regulating 
Mitochondria/Functions 
To assess the distribution, uptake and degradation of 
DNSP-11 in the brain, young adult male F344 rats, as a test 25 
Changes in expression of mitochondrial-associated genes 
in the substantia nigra (SN) of three young adult (5 month 
old) male F344 rats 48 hours following bilateral intranigral 
injections of DNSP-11 into the substantial nigra was 
assessed as follows. organism, received injections of 30 µg DNSP-11 in the 
substantia nigra, hippocampus or cortex. They were eutha-
nized by anesthesia overdose at various time points from 30 
minutes to 48 hrs later and perfused through the heart with 
saline followed by paraformaldehyde. 
Our standard published procedures for immunocyto-
chemical staining were used (e.g. Gash D M et al., J Comp 
Neural. 1995 Dec. 18; 363(3):345-58, Grondin et al., 2002; 
A 3 µg/µl DNSP-11 peptide solution was prepared in 
citrate buffer and filter sterilized. Stereotaxic injections were 
made of 30 µg DNSP-11 in 10 ul citrate buffer into the 
30 substantia nigra on each side of the brain. Controls received 
10 µg injections of vehicle. Forty-eight hours later, the 
animals were euthanized, the brains quickly recovered and 
sectioned so that the bilateral SN could be dissected out as 
Ai et al., 2003). A polyclonal antibody was generated against 35 
DNSP-11 in rabbits (Alpha Diagnostic International, San 
Antonio, Tex.). Endogenous peroxidases were inactivated 
one block of tissue and snap frozen in liquid nitrogen. RNA 
was extracted from the SN samples for gene array analysis, 
which was conducted on Affymetrix Version II chips. A gene 
chip was run for each of the six rats: three bilateral vehicle 
recipients, three bilateral 30 µg DNSP-11 recipients. by incubation with 0.2% hydrogen peroxide (H2 0 2 ) for 10 
minutes and background blocked with 4% normal serum, 
40 
1 % bovine serum albumin (BSA) for 1 hour. Free floating 
Genes regulating mitochondrial functions were identified 
as the subset of genes on the microarray in the peptide-
treated group having expression levels that were signifi-
cantly increased or decreased as compared to the controls 
(Table 5). Fourteen genes were significantly up-regulated 
and five were significantly down-regulated in DNSP-11 
45 recipients. One gene with increased expression was Mono-
amine Oxidase B, a finding consistent with the higher 
DOPAC levels mentioned earlier. A number of other genes 
with increased expression are associated with protection 
sections were incubated in primary antisera. Sections were 
then exposed to the appropriate biotinylated IgG (Vecto 
Labs, Burlingame, Calif.) for 1 hour and then incubated in 
avidin-biotin-peroxidase complex using Elite ABC 
Vectastain Kits (Vector Labs) for 1 hour. Some sections were 
double-labeled using procedures following our published 
procedures for immunocytochemical staining to identify 
cells with two markers (e.g. Ai et al., 2003). 
50 
Controls for immunostaining included the omission of 
against oxidative damage: glutathione/glutaredoxin, gluta-
thione peroxidase and thioredoxin (Koehler et al., Antioxid 
Redox. Signal., 8(5-6):813-22 (2006); Comhair & Erzurum 
primary antibodies and replacement of primary antibodies 
with normal serum of the same species. 
Results: A 30 µg bolus of DNSP-11 injected into the 
mid-substantia nigra region using stereotaxic procedures 
spreads -3 mm in the anterior-posterior plane and up to -2 
mm in the medial-lateral plane (FIG. 17) to cover most of the 
pars compacta component of the nigra. DNSP-11 is taken up 
in the first 30 minutes following injection by neurons and 
their axonal and dendritic processes. It is found in the 
cytoplasm and then perinuclear area and nucleus. At 24 
hours after injection, some residual DNSP-11 can still be 
detected. There was no evidence of DNSP-11 by 48 hours 
post peptide administration. 
Stereotaxic injections of 30 µg DNSP-11 were also made 
into the striatum, hippocampus and cortex. Uptake was 
Antioxid Redox Signal., 7(1-2):72-9. (2005)). Catalase is an 
important enzyme converting the strong oxidant hydrogen 
peroxide to water- and oxygen (Calderon IL et al., Catalases 
55 are NAD(P)H-dependent teliurite reductases. PLoS ONE. 
1 :e70 (2006 Dec. 20)). Peroxyredoxin is another antioxidant 
(Rhee, Chae & Kim, Free Radie Biol Med. 2005 Jun. 15; 
38(12):1543-52. Epub (2005 Mar. 24)). Increased levels of 
Park 7 (DJ-1) are protective against Parkinson's disease 
60 (Thomas & Beal, Hum Mal. Genet. 16 Spec No. 2:R183-94 
(2007 Oct. 15)) and increase levels of Presenilin 1 are 
believed to be protective against Alzheimer's disease (Das, 
Front Biosci. 13:822-32 9 (2008 Jan. 1)). In both instances, 
it is a decreased or mutant form of the gene that is closely 
65 linked to neurodegenerative diseases. The cytochrome c 
oxidase subunits are components of the terminal respiratory 
complex producing energy via oxidative phosphorylation. 
us 9,586,992 B2 
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TABLE 5 
Changes in ex12ression level 12ost DNSP-11 delivea 
SYMBOL DESCRIPTION PEPTIDE CONTROL P-VALUE FOLD CHANGE 
GLRX2 glutaredoxin 2 3618.7 3472.2 <0.001 1.09 
CASP8 caspase 8, apoptosis-related cysteine 219.4 178.1 0.006 1.25 
peptidase 
TXN2 thioredoxin 2 1511.9 1378.5 0.010 1.10 
MAOB monoarnine oxidase B 2199.8 1974.2 0.012 1.13 
COX6A2 cytochrome c oxidase subunit Via 814.1 520.6 0.014 1.75 
polypeptide2 
GPX7 glutathione peroxidase 7 194.2 183.8 O.G15 1.19 
CAT catalase 2828.2 271a.O O.G15 1.09 
PRDX5 peroxiredoxin 5 5569.8 4790.1 0.020 1.13 
PSENl presenilin 1 (Alzheimer disease 3) 673.5 563.2 0.022 1.16 
CASP3 caspase 3, apoptosis-related cysteine 421.4 367.5 0.024 1.18 
peptidase 
COX17 COX! 7 cytochrome c oxidase assembly 2326.1 2017.8 0.025 1.11 
homolog (S. cerevisiae) 
PARK.7 DJ-1 protective against Parkinson's disease 5299.2 5159.4 0.032 1.02 
COX6Bl cytochrome c oxidase subunit Vib 7869.7 7536.6 0.044 1.04 
polypeptide 1 (ubiquitous) 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 3125.4 2943.0 0.046 1.07 
alpha subcomplex, 7, 14.5 kDa 
APP amyloid beta (A4) precursor protein 9734.4 10117.2 0.006 -1.08 
(peptidase nexin-11, Alzheimer disease) 
MAPK9 mitogen-activated protein kinase 9 770.7 930.0 0.007 -1.21 
MAPKlO mitogen-activated protein kinase 10 505.0 552.8 0.008 -1.08 
BACEI beta-site APP-cleaving enzyme 1 451.6 510.6 0.016 -1.09 
MAP2K4 mitogen-activated protein kinase kinase 4 2422.4 2744.4 0.043 -1.12 
Mitochondrial respiration was assessed using a miniature 
3° Clark-type electrode, in a sealed, thermostatic and continu-
ously stirred chamber. Mitochondria were added to the 
chamber to yield a final protein concentration of 1 mg/ml. 
The substrate concentrations were 5.0 mM/2.5 mM for 
The caspases having increased expression are associated 
with apotosis (Kataoka, Crit. Rev Immunol. 25(1):31-58 
(2005); Vassar, Neuron 54(5):671-3 (2007)). Without wish-
ing to be bound by theory, the increased expression of low 
levels capases may reflect a nonspecific inflammatory reac-
tion to the mild physical injury induced by the needle track 
35 
and injection of material into the substantia nigra. 
glutamate/malate and pyruvate/malate or 10 mM for succi-
nate +2.5 µM rotenone or a-glycerophosphate. State 3 
respiration was initiated by the addition of 150 l]mols ADP. 
The respiratory control ratio was calculated as respiration in 
the presence of ADP (state 3)/respiration in absence of ADP 
The foregoing results indicate that DNSP-11 treatment 
significantly effects the expression of genes regulating mito-
chondrial functions. The changes in gene expression would 
be neuroprotective against free radical oxidative damage to 40 
mitochondria. This would decrease mitochondrial wear and 
(state 4). ADP/O ratios were determined by dividing the 
amount of ADP phosphorylated during State III respiration 
tear from oxidative respiratory processes producing energy, 
increasing the functional lifespan of mitochondria in a 
neurons and synapses. 
Example 14 
DNSP-11 Increases State III 
Mitochondria/Respiration in the Rat Nigrostriatal 
System 
As our previous studies had demonstrated that injections 
of 30 µg DNSP-11 into the substantia nigra had marked 
effects 28 days post administration with elevated levels of 
dopamine and dopamine metabolites in the nigrostriatal 
system (substantia nigra and its projections to the striatum), 
we quantified the effects of DNSP-11 on mitochondria 
respiration and enzyme activity in the nigrostriatal system of 
young adult F344 rats at 28 days post injection. 
Six five-month-old male F344 rats received bilateral 
intranigral injections of 30 µg DNSP-11. Six age and sex-
matched controls received injections of the same volume of 
vehicle (citrate buffer). Twenty-eight days after test material 
administration, the animals were euthanized by C02 anes-
thesia and the brain samples rapidly dissected. The striatum 
and substantia nigra were isolated quickly and carefully 
using a rat brain matrix for F344 rats. 
by the amount of oxygen consumed. NAD-linked substrates, 
e.g. glutamate and pyruvate, utilize complexes I, III, IV in 
their oxidation, succinate utilizes complexes II, III, IV and 
45 a-glycerophosphate utilizes III, IV. Thus impaired oxidation 
ofNAD-linked substrates, but normal oxidation of succinate 
or a-glycerophosphate implies a defect at the level of 
complex I. Impaired oxidation of both NAD-linked and 
succinate oxidation implies a defect in both complex I and 
50 II and/or in complex III and IV which can be elucidated by 
the use of a-glycerophosphate. 
The chamber was also equipped with fluorescence/absor-
bance probes which allow us to also measure simultaneously 
ROS production in real-time with all other parameters. ROS 
55 production was measured using the H20 2 indicator dichlo-
rodihydrofluorescein diacetate (H2 DCFDA, Molecular 
Probes). Ten µM H2 DCFDA, which is made fresh before 
each use, was added to the chamber and the relative amount 
of mitochondria) H2 0 2 and free radical production measured 
60 as an increase in fluorescence. Again the same rationale as 
above can be used to pinpoint the source of ROS production. 
Additionally, ROS production was monitored over time in a 
Synergy HT plate reader or a Shimadzu RF-5301 spectro-
fluorimeter with stirred and water-jacketted cuvett holders 
65 (excitation 490 µm, em1ss10ns 526 l]m; ex55011m, 
em59011m, respectively) at 3 7° C. for 15 min in the presence 
of 10 µM H2 DCFDA or Amplex Red, a H2 0 2 indicator that 
US 9,586,992 B2 
33 
is extramitochondrial. Controls include the addition of the 
electron transport chain inhibitor antimycin (complex III 
inhibitor, yields maximum ROS production independent of 
ll W), oligomycin (inhibits ATPase yielding maximum 
llW-dependent ROS production) and the uncoupler FCCP 
(inhibits all llW-dependent ROS production). 
34 
eases, including Alzheimer's disease and Parkinson's dis-
ease, improving cognitive functions in the former and 
improved motor functions in the latter. 
Example 15 
The in vitro studies and in vivo measures of the neuro-
trophic/mitochondrogenic effects of DNSP-11 led us to 
investigate the potential neurorestorative properties of 
10 DNSP-11 to damaged dopamine neurons in a unilateral rat 
model of PD. 
The mitochondria are freeze-thawed and sonicated three 
times for measuring all the complexes activities. Complex I 
(NADH dehydrogenase) assay is performed in 2.5 mM 
KP04 buffer (pH 7.2) containing mitochondrial protein (6 
µg), 5 mM MgC12 , 1 mM KCN, 1 mg/ml BSA, and 150 µM 
NADH at 30° C., the reaction initiated by addition of 
coenzyme Q-1 (50 µM). In this reaction ubiquinone 1 was 
the final electron acceptor. The decrease in NADH absor-
bance at 340 rim was monitored. The assay was also 15 
performed in the presence ofrotenone (10 µM) to determine 
the rotenone-insensitive and the rotenone-sensitive complex 
I enzyme activity. Complex II (succinate dehydrogenase) 
activity was measured by the rate of reduction of 2,6-
Dichloroindophenol. The reaction mixture contained 100 20 
mM KP04 buffer, 20 mM succinate, 10 µM EDTA, 0.01 % 
Triton, 1 µg/100 µl coenzyme Q2 containing mitochondria) 
protein (6 µg) at 30° C. and the reaction was initiated by the 
addition of 0.07% 2,6-Dichloroindophenol. Decreased in 
absorbance was monitored at 600 rim. Complex IV (cy- 25 
tochrome c oxidase) activity was measured in 10 mM KP04 
buffer and 50 µM reduced cytochrome c. The reaction was 
initiated by addition of 6 µg mitochondria) protein. Rate of 
oxidation of cytochrome c was measured by measuring the 
decrease in absorbance of reduced cytochrome c, observed 30 
at 550 nm. 
As shown in FIG. 18, there was a trend towards an 
increase in State III oxidative phosphorylation at 28 days 
post treatment in the substantia nigra. However, with an n=2, 
the difference was not significant with a two-tailed t-test. 35 
The effects reached statistical significance in the striatum, 
which is heavily innervated by dopamine fibers from the 
substantia nigra forming synapses on striatal medium spiny 
neurons. Evidence described in Example 12 indicates that 
DNSP-11 was taken up within 30 minutes into neuritic 40 
processes and cell bodies of neurons. Soon thereafter, immu-
noreactive DNSP-11 was found in the nucleus. The effects 
at 28 days on dopamine and metabolite levels and on 
mitochondria demonstrate that DNSP-11 treatment initiates 
genetic changes that last for long periods, at least one month, 45 
and without wishing to be bound by theory, this may occur 
perhaps through receptors involving transcribing factors. 
Within 30 minutes following a 30 ug injection of DNSP-
11 into the F344 rat substantia nigra, the broad distribution 
Fischer 344 rats received dual-site unilateral injections of 
6-0HDA to produce extensive destruction of the ascending 
dopaminergic system that resulted in a greater than 99% 
depletion of striatal dopamine content ipsilateral to the site 
of the 6-0HDA injections. Rats were tested 3-4 weeks after 
the injection of 6-0HDA using low-dose (0.05 mg/kg, i.p.) 
apomorphine to induce rotational behavior. In rats that 
rotated greater than 300 turns/60 minutes, 30 µg ofDNSP-11 
was injected into the ipsilateral substantia nigra. DNSP-11 
produced a significant -50% decrease in apomorphine-
induced rotational behavior that was significant 1 week after 
administration and this effect was maintained for at least 4 
weeks after DNSP-11 (FIG. 19A). At 5 weeks, the substantia 
nigra and striatum from each rat was analyzed by high 
performance liquid chromatography coupled with electro-
chemical detection. A single injection of DNSP-11 was 
found to significantly increase levels of dopamine and the 
dopamine metabolite, DOPAC, by -100% in the substantia 
nigra, supporting that DNSP-11 has a powerful neuro-
trophic-like/mitochondrogenic restorative effect on dop-
amine neurons in this animal model of late stage PD (FIG. 
19B). 
In summary, the evidence reported in this patent applica-
tion demonstrates the ability of DNSP-11 treatment to 
improve mitochondrial functions and supports the ability of 
DNSP-11 treatment to promote behavioral restoration in 
Alzheimer's disease, Parkinson's disease and aging pro-
cesses. 
Our results demonstrate that DNSP-11 is taken up by 
neurons in the cortex, hippocampus and substantia 
nigra, areas important in cognitive and motor functions; 
Our results demonstrate that DNSP-11 significantly 
increases the expression of genes associated with mito-
chondrial functions in the brain, including genes for 
proteins that protect mitochondria from oxidative dam-
age leading to functional deterioration; 
Our results demonstrate that DNSP-11 increases energy 
production in brain mitochondria for extended periods. 
Increased energy production in mitochondria in synapses 
is posited to promote restoration of neural circuitry 
leading to restoration of cognitive and motor functions. 
While the present invention has been described with 
of the compound through the substantia nigra (SN) region of 50 
the midbrain was evident (FIG. 17, panels A, B). At higher 
magnification (FIG. 17 panels C, D) uptake of the peptide by 
neurons (arrows) could be discerned. At very high magni-
fication (FIG. 17 panel E), punctuate-immunoreactive stain-
ing of DNSP-11 was present in neuritic processes, cyto-
plasm and the perinuclear area of the cell body (arrows). The 
pattern of immunoreactivity was similar at 90 minutes post 
injection (FIG. 17 panel B), with prominent labeling in 
DNSP-11 in cells and neuritic processes (FIG. 17, panel D). 
Immunostaining was more sensitive using fluorescent tech-
niques (FIG. 17, panel F), highlighting DNSP-11 immuno-
reactivity in the cytoplasm and nuclei of neurons. The cells 
55 reference to specific embodiments, this application is 
intended to cover those various changes and substitutions 
that may be made by those of ordinary skill in the art without 
departing from the spirit and scope of the appended claims. 
in F were double-labeled for the neuronal marker NeuN and 
DNSP-11. 
By improving mitochondrial functions in neurons and 
their synapses, DNSP-11 treatment could significantly 
restore neural networks affected in neurodegenerative dis-
The publications discussed herein are provided solely for 
60 their disclosure prior to the filing date of the present appli-
cation. Nothing herein is to be construed as an admission 
that the present invention is not entitled to antedate such 
publication by virtue of prior invention. Further, the dates of 
publication provided may be different from the actual pub-
65 lication dates, which may need to be independently con-
firmed. All publications cited herein are hereby incorporated 
by reference in their entirety. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 15 
<210> SEQ ID NO 1 
<211> LENGTH, 134 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg 
1 5 10 15 
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg 
20 25 30 
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu 
35 40 45 
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile 
50 55 60 
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp 
65 70 75 80 
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys 
85 90 95 
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser 
100 105 110 
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala 
115 120 125 
Lys Arg Cys Gly Cys Ile 
130 
<210> SEQ ID NO 2 
<211> LENGTH, 17 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 2 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys 
<210> SEQ ID NO 3 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 3 
Phe Pro Leu Pro Ala 
1 5 
<210> SEQ ID NO 4 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 4 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu 
36 
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-continued 
1 
<210> SEQ ID NO 5 
<211> LENGTH, 402 
<212> TYPE, DNA 
5 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) .. (402) 
<400> SEQUENCE, 5 
10 
tea cca gat aaa caa atg gca gtg ctt cct aga aga gag egg aat egg 48 
Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg 
1 5 10 15 
cag get gca get gee aac cca gag aat tee aga gga aaa ggt egg aga 96 
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg 
20 25 30 
ggc cag agg ggc aaa aac egg ggt tgt gtc tta act gca ata cat tta 144 
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu 
35 40 45 
aat gtc act gac ttg ggt ctg ggc tat gaa ace aag gag gaa ctg att 192 
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile 
50 55 60 
ttt agg tac tgc age ggc tct tgc gat gca get gag aca acg tac gac 240 
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp 
65 70 75 80 
aaa ata ttg aaa aac tta tee aga aat aga agg ctg gtg agt gac aaa 288 
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys 
85 90 95 
gta ggg cag gca tgt tgc aga ccc ate gee ttt gat gat gac ctg tcg 336 
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser 
100 105 110 
ttt tta gat gat aac ctg gtt tac cat att eta aga aag cat tee get 384 
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala 
115 120 125 
aaa agg tgt gga tgt ate 402 
Lys Arg Cys Gly Cys Ile 
130 
<210> SEQ ID NO 6 
<211> LENGTH, 211 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
Met Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr 
1 5 10 15 
Ala Ser Ala Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro 
20 25 30 
Ala Glu Asp Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser 
35 40 45 
Ser Asp Ser Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val 
50 55 60 
Met Asp Phe Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp 
65 70 75 80 
Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala 
85 90 95 
Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg 
100 105 110 
Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr 
38 
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39 
-continued 
115 120 125 
Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr 
130 135 140 
Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu 
145 150 155 160 
Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln 
165 170 175 
Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp 
180 185 190 
Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys 
195 200 205 
Gly Cys Ile 
210 
<210> SEQ ID NO 7 
<211> LENGTH, 192 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp 
1 5 10 15 
Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser Ser Asp Ser 
20 25 30 
Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val Met Asp Phe 
35 40 45 
Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp Lys Gln Met 
50 55 60 
Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn 
65 70 75 80 
Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg Gly Lys Asn 
85 90 95 
Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly 
100 105 110 
Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly 
115 120 125 
Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu 
130 135 140 
Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys 
145 150 155 160 
Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu 
165 170 175 
Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys Ile 
180 185 190 
<210> SEQ ID NO 8 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 8 
Phe Pro Leu Pro Ala Gly Lys Arg 
1 5 
40 
<210> SEQ ID NO 9 
<211> LENGTH, 14 
<212> TYPE, PRT 
41 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,586,992 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 9 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg 
1 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, PRT 
5 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
10 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 10 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys Gly Arg Arg 
20 
<210> SEQ ID NO 11 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 11 
Phe Pro Leu Pro Ala Gly 
1 5 
<210> SEQ ID NO 12 
<211> LENGTH, 12 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 12 
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly 
1 5 10 
<210> SEQ ID NO 13 
<211> LENGTH, 18 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 13 
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly 
1 5 10 15 
Lys Gly 
<210> SEQ ID NO 14 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
42 
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43 44 
-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 14 
Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg 
1 5 10 15 
<210> SEQ ID NO 15 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 15 
Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser 
1 5 10 15 
Arg Gly Lys Gly Arg Arg 
20 
What is claimed is: 25 
1. A method for promoting the survival and/or function of 
dopaminergic neurons, comprising administering to a sub-
ject in need thereof a pharmaceutically effective amount of 
a composition comprising at least one of the following 
peptides: 30 
(a) a purified Amidated Dopamine Neuron Stimulating 
peptide (ADNS peptide) comprising the amino acid 
sequence ERNRQAAAANPENSRGK-amide (SEQ ID 
NO: 2); 
(b) a purified ADNS peptide comprising the amino acid 35 
sequence FPLPA-amide (SEQ ID NO: 3); and 
wherein said composition further comprises at least one of 
a pharmaceutically acceptable vehicle, excipient, and 
diluent, 
wherein the brain disease or injury is at least one condi-
tion selected from the group consisting of Parkinson's 
Disease, Alzheimer's disease, and Amyotrophic Lateral 
Sclerosis (ALS); and 
wherein the composition is administered in an amount 
sufficient to increase the level of at least one of dop-
amine and a dopamine metabolite in the subject. 
4. The method of claim 3 wherein the composition 
comprises a purified ADNS peptide comprising the amino 
acid sequence PPEAPAEDRSL-amide (SEQ ID NO: 4). 
( c) a purified ADNS peptide comprising the amino acid 
sequence PPEAPAEDRSL-amide (SEQ ID NO: 4) 
wherein the composition is administered to a subject 
having at least one condition selected from the group 
consisting of Parkinson's Disease, Alzheimer's disease, 
and Amyotrophic Lateral Sclerosis (ALS); and 
5. A method of increasing levels of at least one of 
dopamine and a dopamine metabolite in a subject having 
40 damaged dopamine neurons comprising 
administering a pharmaceutically effective amount of a 
composition comprising a purified peptide comprising 
the amino acid sequence PPEAPAEDRSL-amide (SEQ 
ID NO: 4) and at least one of a pharmaceutically wherein the composition is administered in an amount 
sufficient to increase the level of at least one of dop-
amine and a dopamine metabolite in the subject. 45 
2. The method of claim 1 wherein the composition 
comprises a purified ADNS peptide comprising the amino 
acid sequence PPEAPAEDRSL-amide (SEQ ID NO: 4). 
3. A method for treating a brain disease or injury resulting 
in dopaminergic deficiencies, comprising administering to a 50 
subject in need thereof a pharmaceutically effective amount 
of a composition comprising at least one of the following 
peptides: 
acceptable vehicle, excipient, and diluent, 
wherein the damaged dopamine neurons are associated 
with at least one condition selected from the group 
consisting of Parkinson's Disease, Alzheimer's disease, 
and Amyotrophic Lateral Sclerosis (ALS); and 
wherein the composition is administered in an amount 
sufficient to increase the level of at least one of dop-
amine and a dopamine metabolite in the subject. 
6. The method of claim 1, wherein the level of at least one 
of dopamine and a dopamine metabolite is measured by 
microdialysis. 
7. The method of claim 3, wherein the level of at least one 
of dopamine and a dopamine metabolite is measured by 
microdialysis. 
(a) a purified Amidated Dopamine Neuron Stimulating 
peptide (ADNS peptide) comprising the amino acid 55 
sequence ERNRQAAAANPENSRGK-amide (SEQ ID 
NO: 2); 
8. The method of claim 5, wherein the level of at least one 
of dopamine and a dopamine metabolite is measured by 
60 microdialysis. 
(b) a purified ADNS peptide comprising the amino acid 
sequence FPLPA-amide (SEQ ID NO: 3); and 
( c) a purified ADNS peptide comprising the amino acid 
sequence PPEAPAEDRSL-amide (SEQ ID NO: 4); * * * * * 
